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ABSTRACT OF DISSERTATION 
 
 
NEW INSIGHTS INTO POST-SEPSIS MUSCLE WEAKNESS ELUCIDATED 
USING A NOVEL ANIMAL MODEL 
Sepsis is a severe life-threatening critical illness that damages multiple 
physiological systems.  After hospital discharge, more than 70% of severe sepsis 
survivors report profound weakness which significantly impacts quality of life.  
Such weakness gives rise to new limitations of daily living, which ultimately leads 
to loss of independence in many patients.  Despite wide recognition of this 
serious issue by clinicians and researchers alike, the mechanisms contributing to 
chronic skeletal muscle dysfunction after sepsis are not well understood.  Lack of 
progress in this field is largely due to the absence of an appropriate animal 
model; current models are either too mild to induce muscle weakness or too 
severe and cause death within a few days.  As such, this dissertation work first 
focused on establishing a clinically-relevant animal model of sepsis which yields 
surviving mice with chronic skeletal muscle weakness (Aim 1).  This aim involved 
refining the cecal slurry injection model of polymicrobial sepsis in young adult 
animals, as well as optimizing the timing, duration, and dose of multiple 
therapeutic agents.  The resulting resuscitation protocol was adapted for use in 
late-middle-aged animals, and muscle strength was evaluated using an ex vivo 
system which confirmed significant muscle weakness in sepsis survivors, long 
after sepsis was resolved.  Next, using this novel model, we sought to 
characterize sepsis-induced long-term muscle dysfunction at the molecular level 
(Aim 2).  The first set of experiments under this aim was designed to identify the 
primary global mechanism(s) (i.e. atrophy, polyneuropathy, and/or myopathy) 
responsible for muscle weakness in sepsis survivors. Analysis of the force-
frequency curves and specific force measurements led to the conclusion that 
myopathy is the primary cause.  Electron micrograph observation, functional 
assays, and protein analysis then showed that sepsis survivors’ skeletal muscles 
are characterized by profound mitochondrial abnormalities and oxidative 
damage.  Collectively, these studies demonstrate that long-term muscle 
weakness is apparent in sepsis-surviving animals, and the functional decline is 
associated with unresolved mitochondrial damage and dysfunction.  This work 
suggests that medical treatments beyond targeting muscle wasting alone could 
allow sepsis survivors to regain function and return to productive lives. 
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CHAPTER 1 
Introduction and Hypothesis 
 
1.1 Sepsis 
1.1.1 Pathogenesis of sepsis 
Sepsis is a life-threatening condition that develops when the immune 
system fails to resolve a local infection, and the infection spreads.  The most 
common primary source of infection is pneumonia (i.e. respiratory infections; 
29% of cases), with others being urinary tract infections (i.e. genitourinary 
infections; 20.5%) and gastrointestinal infections (15.1%; Martin et al 2006).  
Additionally, complications from surgical procedures also contribute to sepsis 
cases (Elixhauser et al 2011), as do infections which develop after trauma or 
burn injury.  Infections with antibiotic resistant bacteria are becoming increasingly 
more common causes of sepsis, where Methicillin-resistant Staphylococcus 
aureus (MRSA) is the second most commonly identified organism in sepsis 
cases (Elixhauser et al 2011).  Many cases are polymicrobial in nature, as 
opposed to being caused by a single organism (Angus et al 2001; Esper et al 
2006; Starr & Saito 2013).  Sepsis can also result from non-bacterial sources of 
infection, including viral and fungal infections insults (Bone et al 1992; Martin et 
al 2006). In approximately half of sepsis cases, however, the specific pathogen is 
never identified (Elixhauser et al 2011).   
Sepsis is often termed an “infection of the bloodstream,” which is the 
definition of bacteremia.  However, sepsis is further characterized by the 
progressive dysregulated host immune response to the infectious stimulus which 
results in systemic inflammatory response syndrome (SIRS).  Profound elevation 
of proinflammatory cytokines cause platelet activation and damage to endothelial 
cells, resulting in coagulation and hypotension.  If not resolved, the condition 
progresses to severe and often times irreversible tissue damage due to hypoxia 
and oxidative stress, which contribute to the development of multi-organ failure 
(MOF) and death (Figure 1.1).    
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Figure 1.1.  Progression of sepsis pathogenesis.  The sepsis condition 
results when the immune system fails to contain a local infection, which 
spreads to the blood stream (i.e. bacteremia) and triggers a profound 
inflammatory response, characterized by strikingly elevated levels of 
proinflammatory cytokines.  Left unresolved, coagulation and edema 
contribute to the development of hypotension, often causing irreversible tissue 
damage, including in the skeletal muscle.  Ultimately these factors can 
contribute to the development of multi-organ failure and subsequent death.  
Adapted from Buras et al 2006.   
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As such, sepsis is defined as a life-threatening organ dysfunction caused 
by a dysregulated host response to infection (Singer et al 2016).  Clinically, organ 
dysfunction is identified as an increase in the Sequential Organ Failure 
Assessment (SOFA) score of ≥ 2 points (Seymour et al 2016; Singer et al 2016).  
Septic shock is a subset of sepsis cases in which patients have severe 
circulatory, cellular, and metabolic abnormalities which are associated with 
increased sepsis-associated mortality (Shankar-Hari et al 2016) which occurs in 
approximately 20% of sepsis patients (Shankar-Hari et al 2017; Angus et al 
2001).  Patients with septic shock are identified by having hypotension which 
requires vasopressor therapy to maintain mean blood pressure of 65 mmHg or 
3 
greater, and having serum lactate level of > 2 mmol/L after adequate fluid 
resuscitation (Shankar-Hari et al 2016). 
 
1.1.2 Sepsis epidemiology and survival outcomes 
Every year, nearly 1.7 million patients are diagnosed with sepsis in the US 
when taking into account both primary and secondary diagnoses (836,000 and 
829,000 cases, respectively; Elixhauser et al 2011).  The majority of sepsis 
cases and deaths are among the elderly population, as both incidence and 
mortality increase with age (Martin et al 2003).  The incidence rate is increasing 
by approximately 9 to 13% annually (Martin et al 2003; Gaieski et al 2013; Angus 
et al 2001) with an average of 4,600 new patients being treated for sepsis every 
day (Elixhauser et al 2011).  This increase in incidence exceeds the rate of 
population expansion, and is attributed to a variety of factors including increased 
ability to diagnose the condition, rising trend of invasive surgical procedures, an 
expanding elderly population (explained further below in Section 1.4), as well as 
increased population with immune disorders and heightened risk of antibiotic 
resistant bacteria (Martin et al 2006).   
Although the sepsis incidence rate continues to climb, improved case 
definitions (i.e. diagnosis criteria) and advances in critical care medicine have led 
to a decline of the mortality rate in recent decades (Angus et al 2001).  The 
sepsis mortality rate remains high compared to stays in the ICU for other 
conditions (approximately 8-times higher; Elixhauser et al 2011).  Thus, a 
significant amount of work remains to further understand the pathophysiology of 
sepsis to develop pharmacological interventions and further decrease the short-
term mortality rate (Angus et al 2001).  It has also become a priority to 
understand the challenges of sepsis survivors after hospital discharge.  The 
combination of the increased incidence and decreased mortality resulted in over 
1.5 million sepsis survivors discharged from US hospitals in 2012; which is more 
than two-fold higher compared to the previous decade (Figure 1.2 B; Elixhauser 
et al 2011; Stoller et al 2016).   
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Figure 1.2.  The number of sepsis survivors in the US has doubled within 
the past decade.  The sepsis incidence rate has continued to rise, whereas 
the mortality rate has steadily decreased over recent years (A; reproduced 
from Stoller et al. 2016).  Such trends have resulted in a doubling of the 
number of sepsis survivors being discharged from US hospitals, illustrated by 
number of discharges in 2012 compared to 2000 (B).  Data adapted from 
Elixhauser et al. 2011 and Stoller et al. 2016. 
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1.2 Chronic muscle weakness after sepsis 
1.2.1 Muscle weakness in patients with sepsis during their stay in the ICU 
Physicians first reported muscle weakness in critically ill patients with 
sepsis and multi-organ failure (MOF) three decades ago (Bolton et al 1984).  
Since then, this phenomenon has been demonstrated using a variety of methods.  
Lanone et al. showed significant reductions in sub-maximal (30-Hz stimulation) 
force generation capacity in rectus abdominus muscle biopsies obtained from 
septic patients compared to biopsies taken from non-sepsis controls who were 
undergoing elective laparotomy or cardiac surgery (Lanone et al 2000).  
Eikermann et al. conducted standard electrophysiological tests in the adductor 
pollicis muscle (located in the hand) by ulnar nerve stimulation in sepsis patients 
5 
with multi-organ failure (MOF) and age-matched healthy controls whose arm and 
thumb were immobilized for 14 days using a lower arm cast.  This group found 
that sepsis patients had a 30% reduction in force generation capacity compared 
to immobilized controls, demonstrating that disuse alone cannot explain sepsis-
induced muscle weakness (Eikermann et al 2006).  Baldwin and Bersten (2014) 
evaluated strength in patients with sepsis who had been mechanically ventilated 
for at least 5 days during their hospital stay. They analyzed peripheral muscle 
strength by isometric handgrip test and elbow flexion, both of which were 
significantly reduced in sepsis patients with a similar trend in knee extension 
force compared to age and sex matched healthy controls.   Although each of 
these studies has limitations, they clearly indicate that sepsis induces severe 
muscle weakness. 
Intensive care unit-acquired weakness (ICUAW) and muscle wasting are 
complications which arise due to immobilization during bedrest, sedation, and 
disuse, as well as specific pharmacological interventions and fasting (Schefold & 
Bierbrauer 2010). However, sepsis is further complicated due to its 
pathophysiology and pharmaceutical interventions, leading to the development of 
critical illness myopathy (CIM; Eikermann et al 2006).  More specifically, 
elevation of proinflammatory cytokines, such as interleukin-6 (IL-6) and tumor 
necrosis factor alpha (TNF-α) contribute to impaired insulin resistance which has 
been linked to decreased mammalian target of rapamycin (mTOR) signaling and 
therefore decreased skeletal muscle protein synthesis (Spranger et al 2003; 
Frost et al 2005; Frost et al 2008; Lang et al 2007; Schefold & Bierbrauer 2010).  
Sepsis-associated cytokinemia not only decreases protein synthesis (Lang et al 
2007; Vary & Kimball 1992), it also stimulates protein degradation through 
multiple pathways, including lysosomal degredation (Ebisui et al 1995), ubiquitin 
proteasome (Klaude et al 2007), and apoptotic pathways (Comstock et al 1998).  
To further complicate the matter, many patients require mechanical ventilation, 
further causing disuse-mediated atrophy and weakness (Callahan & Supinski 
2009).  These changes in muscle protein synthesis and breakdown result in 
muscle wasting beyond that which is seen in the ICU for other conditions, 
6 
however nutritional support aimed at stimulating protein synthesis does not 
effectively restore balance (Lang et al 2007; Schefold & Bierbrauer 2010; Ash & 
Griffin 1989; Minnaard et al. 2005).  Further, animals which are pair-fed to 
animals with sepsis do not have muscle weight loss (Voisin et al 1996), 
demonstrating that therapeutic interventions beyond nutritional supplementation 
and more specific to sepsis pathophysiology are necessary to prevent and/or 
recover muscle weakness in patients with sepsis. 
Beyond sepsis-associated imbalances in protein degradation and 
synthesis, sepsis-mediated inflammation, as well as tissue hypoxia caused by 
coagulation and vascular endothelium damage, trigger the production of reactive 
oxygen species (ROS) and reactive nitrogen species (RNS) which cause severe 
oxidative damage to many cell types, including the motor unit (Lanone et al 2000; 
Singer 2014; Fredriksson et al 2008).  Oxidative damage to the peripheral nerve 
and/or neuromuscular junction results in polyneuropathy, also referred to as 
critical illness polyneuropathy (CIP), which results in desensitization of sensory 
nerve amplitudes and thus decreased force (Garnacho-Montero et al 2001).  
Although many cases of polyneuropathy have been reported, it only occurs in a 
small fraction of patients (Koch et al 2011).   
Being that skeletal muscle is highly oxidative (the largest consumer of 
oxygen in the body), generation of free radicals is more pronounced compared to 
other tissues (Doria et al 2012; Fulle et al 2014).Therefore, it is not surprising that 
sepsis-induced oxidative stress also causes damage to numerous sites on the 
myofibrillar level that may result in reduced force generation capacity in sepsis 
patients.  The proinflammatory cytokine TNFα has been shown to trigger free 
radical production that causes damage to sarcomeric (i.e. contractile) proteins, 
which hinders muscle contraction and force production (Callahan et al. 2001; 
Hardin et al 2008; Callahan & Supinski 2009).    This is of particular concern 
since skeletal muscle proteins scavenge as much as 50-75% of ROS during 
acute oxidative stress, inducing structural changes to actin and isoforms of 
myosin heavy chain (Dalle-Donne et al 2003), likely having large impacts on 
muscle contraction.   
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 Sepsis-induced oxidative stress also damages skeletal muscle 
mitochondria (Mela 1979; Singer 1999; Boveris et al 2002).  Such damage 
results in impaired mitochondrial function (i.e. reduced oxidative phosphorylation) 
as Fredriksson et al. (2006) showed in patients with sepsis and MOF who had 
40% lower levels of adenosine triphosphate (ATP) in leg muscle (vastus 
lateralis).  Complex I-driven electron transport chain activity (i.e. nicotinamide 
adenine dinucleotide (NAD) dehydrogenase activity) is more impaired by sepsis 
than is complex-II driven activity (i.e. succinate dehydrogenase (SDH) activity; 
Poderoso 1978; Boveris 2002).  These reports are supported by ex vivo 
experiments in which isolated mitochondria cultured with nitric oxide synthase 
(NOS) decreased respiration rates, whereas culturing with NOS-inhibitors 
resulted in increased respiratory rates (Giulivi et al 1998; Boveris et al 2002), 
demonstrating the effect of oxidative stress on mitochondrial function.  
Fredriksson later reported in 2008 that reduction in mitochondrial respiration is 
not associated with differences in mitochondrial enzyme subunits.  Instead, they 
found that mitochondrial biogenesis was upregulated in sepsis patients, but there 
was a loss of its coordination, leading to immature mitochondrial networks and 
increased protease activity.  Not surprisingly, the mitochondria were also 
characterized by low levels of reduced glutathione (GSH), indicating that 
endogenous mitochondrial anti-oxidant capabilities are exhausted during sepsis 
(Brealey et al 2002).  With reduced anti-oxidant capacity, mitochondria are 
further exposed to oxidative damage, especially complex I, which is especially 
susceptible to damage by RNS (Bolanos et al 1997).  Further, since mitochondria 
produce ROS as a byproduct of oxidative phosphorylation, damaged 
mitochondria generate an abundance of free radicals, causing additional damage 
to mitochondria and nearby proteins.  Since muscle contraction is an ATP-
dependent process, reduced energy availability results in reduced muscle force 
generation capacity. 
Also, the sarcoplasmic reticulum is subject to oxidative damage because 
the skeletal muscle ryanodine receptor is highly reactive to nitric oxide and 
hydrogen peroxide (Hamilton et al 2000).  Release of calcium from the 
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sarcoplasmic reticulum upon efferent signaling is essential for muscle function 
whereby it binds troponin on the thin filament, exposing the myosin binding site 
and allows the cross-bridge cycle to occur for muscle contraction.  Thus, 
oxidative damage to the sarcoplasmic reticulum may alter calcium dynamics and 
result in reduced muscle contraction in sepsis patients (Cohen et al 2006; 
Callahan & Supinski 2009).   
In addition to the complex pathophysiology of sepsis which contribute to 
development of muscle weakness, pharmacological interventions may also play 
a role in this phenomenon (Schefold & Bierbrauer 2010).  Although controversial, 
treatment with glucocorticoids has been implicated as a predictor of muscle 
weakness (de Jonghe et al 2002), which other groups suggest is a dose-
dependent issue (Weber-Carstens et al 2010).  On the other hand, use of 
neuromuscular blockers has also been associated with increased risk for 
development of muscle weakness (Segredo et al 1992), but its involvement is 
also not well understood (de Jonghe et al 2009; Schefold & Bierbrauer 2010).   
Thus, sepsis pathogenesis and pharmacological treatments likely further 
propagate muscle weakness beyond what is mediated through disuse alone.  
Sepsis-induced muscle weakness is a complex situation in which numerous 
factors may contribute to the development of decreased muscle contraction, 
including suppressed protein synthesis, increased protein degradation, oxidative 
damage to multiple organelles and contractile proteins, and treatment with 
corticosteroids and neuromuscular blockers which seem to further increase risk 
of the development of muscle dysfunction.   
 
1.2.2 Persistent muscle weakness and chronic disability in sepsis survivors 
Not only do sepsis patients have significant muscle weakness, it is now 
largely acknowledged that the majority of patients who survive septic shock have 
prolonged muscle weakness that persists for years (Callahan & Supinski 2009).  
Koch et al (2011) showed that upon hospital discharge, the majority of patients 
did not recover muscle strength as evaluated using the Medical Research 
Council (MRC) scale.  Strikingly, sepsis-induced muscle weakness is so 
9 
substantial that 23% of sepsis survivors who were functionally independent prior 
to becoming septic developed functional dependency and were discharged to 
nursing care facilities, and an additional 23% were discharged home with home 
care (Odden et al 2013).  Patients who had limitations in activities of daily living 
(ADLs) prior to hospitalization for sepsis were at an even higher risk for being 
discharged to nursing care facilities (56%, p =0.009 vs. patients with no previous 
functional dysfunction; Odden et al 2013).  Heyland et al. (2000) found that 
sepsis survivors had significantly reduced health-related quality of life (HQRL) 
scores, especially in terms of physical functioning, general health, and vitality, 
two-weeks after hospital discharge.  Even further, Iwashyna et al. (2010) 
conducted a prospective study of over 500 sepsis patients and found that 
patients continued to develop functional limitations during the 5-year-long study 
following hospital discharge, a trend which was not observed in non-sepsis 
cases.   ADLs include ability to walk, dress, bathe, prepare meals, use the 
restroom or go to bed without assistance, as well as use the telephone, take 
medications, and manage money; thus development of limitations in any singular 
area would be life-altering, and development of multiple limitations is especially 
devastating, as is the case for septic shock survivors (Iwashyna et al 2010).   
Battle et al. (2014) recently sought to evaluate the influence of sepsis 
severity on long-term (6 months to two years) physical/functional health.  They 
conducted a prospective study which controlled for age, length of stay in the ICU, 
and comorbidities, and compared physical and cognitive outcomes in three 
groups: patients with sterile SIRS, patients with uncomplicated sepsis (i.e. 
without evidence of organ dysfunction), and patients with septic shock.  
Evaluation of physical function, bodily pain, general health, and vitality (assessed 
using a standard health survey (short form-12)) showed that the septic shock 
survivors had significantly lower scores compared to both the sterile SIRS group 
and patients with uncomplicated sepsis, as demonstrated in Figure 1.3.  These 
data clearly show that patients with more severe cases of sepsis are at higher 
risk for developing functional limitations during hospitalization as well as in the 
years following recovery from sepsis pathogenesis itself. 
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Figure 1.3.  Increased sepsis severity is associated with more profound 
reductions in health-related quality of life.  Patients with sterile systemic 
inflammatory response syndrome (SIRS), uncomplicated sepsis, and septic 
shock were recruited to take a survey within 6 months to 2 years following 
hospital discharge to evaluate physical and mental health.  Results from the 
physical components of that survey are shown, with data expressed as means 
± SD.  † signifies p<0.05 SIRS vs. uncomplicated sepsis, ♦ signifies p<0.05 
SIRS vs. septic shock, and # signifies p<0.05 uncomplicated sepsis vs. septic 
shock.  This work is adapted from Battle et al. 2014 used under international 
license CC BY 4.0. 
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Figure 1.4.  The lack of an appropriate animal model of sepsis has been a 
critical barrier to evaluating mechanisms of long-term muscle weakness 
in sepsis survivors.  Induction of mild sepsis results in high survival but not 
organ injury (left arm).  However, induction of severe sepsis without 
therapeutic intervention results in early death, and therefore long-term studies 
cannot be performed (middle arm).  We hypothesized that if severe sepsis 
was induced, and therapeutic intervention was delayed but conducted 
similarly to ICU-care, the majority of animals would survive and long-term 
studies could be performed (right arm).   
 
Severe
No intervention
Experimental sepsis
Mild
With intervention
Good survival
No severe 
damage
Poor survival
Cannot assess 
damage
Good survival
Can assess 
damage
1.3 Lack of an appropriate animal model as limitation of previous studies 
The scientific community acknowledges that sepsis-induced muscle 
weakness is a problem. However, the field lacks an animal model of sepsis that 
induces organ damage but also high survival, which has been a critical barrier to 
identifying the mechanisms responsible for long-term muscle dysfunction.  The 
first major problem with current animal models is that they are either severe 
models causing early death of most animals, or are mild models which only 
cause weakness during sepsis, neither of which are appropriate to understand 
mechanisms of long-term sepsis-induced muscle dysfunction (Figure 1.4).  With 
existing models, the majority of research in the field has focused on mechanisms 
of atrophy (i.e. muscle wasting) during the acute phase, and the small number of 
studies which are conducted in late phases do not include functional analyses 
(Table 1.1), thus no associations can be made about actual muscle weakness.   
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Table 1.1 Muscle studies using current animal models of sepsis 
 
i.p., intraperitoneal; EDL, extensor digitorum longus; TA, tibialis anterior; GM, 
gastrocnemius; FHL, flexor halluces longus.  Adapted from Holecek 2012, with 
additions of studies in blue rows. 
Model Dose/severity Species Time-point(s) Results Reference
E. coli ↑ myofibrillar proteolysis (EDL) 
10 mg/kg i.p. ↑ mRNA for ubiquitin (EDL)
E. coli ↓ mass & protein content (diaphragm; 96 h)
12 mg/kg i.p. ↑ proteolysis (48 & 96 h)
↑ caspase-3 activity (diaphragm)
E. coli ↓ muscle mass & protein content (EDL, TA)
3 mg/kg i.p. (at 24, 48, and 72 h)
E. coli ↓ protein synthesis (maximum at 30 h; GM)
3 mg/kg s.c. ↑ protein degradation (maximum at 24 h; GM)
E. coli ↑ protein synthesis (soleus, EDL)
0.08 mg/kg i.v. ↓ protein degradation (soleus, EDL)
S. enteritidis ↓ protein synthesis (GM)
2 mg/kg i.p. ↑ whole-body proteolysis
0.1 mg/kg i.v.
P. aeruginosa ↓ mass & protein content (GM; 18 h)
1 mg/kg i.p. ↑ mRNA for ubiquitin (GM; 12 h)
E. coli ↓ protein synthesis (GM)
25 µg/ animal
E. coli ↑ atrogin-1 & MuRF1 expression (ubiquitin)
10 mg/kg i.p.
Zymosan no effect on specific force
300 mg/kg i.p. ↓ CSA of type 2 fibers (TA, day 6)
Not provided ↓ dose-dependent  force production 
4 to 16 mg/kg i.p. (diaphragm, FHL)
E. coli ↓ muscle mass (soleus, EDL, TA)
i.v.
S. aureus ↑ proteolysis (GM)
i.m.
E. coli & B. fragilis ↓ protein synthesis (GM, not soleus)
Fecal-agar pellet
Diluted CS ↓ whole-body metabolism
20 mL/kg ↓ force production (diaphragm, 24 h)
↓ MT membrane potential (diaphragm)
↑ proteolysis (EDL)
↑ proteolysis (EDL)
No effect on protein synthesis (soleus, EDL)
↑ proteolysis (soleus, EDL)
↓ protein synthesis (soleus, EDL)
↓ mass & protein content (GM)
↑ atrogin-1 & MuRF1 expression (ubiquitin)
Mouse 7 days ↓ mass (GM) Lang et al.  2010
↓ inspiratory pressure (6 hours)
↓ ETC activity (diaphragm, quadriceps; 48 h)
Supinski et al. 1996
Endotoxemia 
(lipopolysaccharide)
Rat
2 hours,                  
2, 6, & 11 days Minnaard et al. 2004
Cecal ligation and 
puncture
Mouse 5 days Nystrom et al. 2009
Peruchi et al. 2011Rat ≤ 48 hours
Fisher et al. 2000; 
Fareed et al. 2006
16 hoursRat 
Rat 18 hours Safranek et al. 2006
Rat 18 hours Kadlicikova et al. 2004
Live bacteria 
administration
Cecal slurry 
administration 
(polymicrobial)
Mouse
5 days
≤ 72 hours Zolfaghari et al. 2015
Rat 2, 6, 10 days Activation of ubiquitination and lysosomal 
proteolysis
Voisin et al. 1996
Mouse 24 hours Khal & Tisdale (2008)
Mouse 24 hours Kim et al. 2012
Vary & Kimball 1992Rat
Hamsters 72 hours
Mouse 12 & 18 hours Jin & Li 2007
Mouse 4 hours Lang et al. 2010
Rat 18 hours Ash & Griffin 1989
Rat 3.5 hours Holecek et al. 2000
Rat 6, 24, 48, 72 hours Macallan et al. 1996
Rat 6 to 72 hours Jepson et al. 1986
Rat 2, 6, & 12 hours Chai et al. 2003
Rat 48 & 96 hours Supinski et al. 2009
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Some protocols include antibiotic regimens, but are often initiated very 
soon after induction of the infection, and thus block the progression of sepsis 
pathogenesis and stray very far from the clinical situation.  It is important to note 
that in the treatment of clinical sepsis, antibiotics are administered as early as 
possible after recognition of sepsis or septic shock as per the guidelines of the 
Surviving Sepsis Campaign (Dellinger et al 2008).  Retrospective analysis of 165 
ICUs in Europe, the United States, and South America showed that 26.3% of 
patients were treated within the first hour, and the majority (68.6%) of patients 
was treated within three hours after recognition of sepsis condition.  This was 
based on the wide evidence that delay in treatment with antibiotics is linearly 
correlated with increased in-hospital mortality (Kumar et al 2006; Gaieski et al 
2010; Ferrer et al 2014).  However, this early intervention is after recognition of 
sepsis, not after initiation of infection; therefore intervention in animal models 
should be based on timing after development of sepsis, not after infectious insult.  
Other protocols include antibiotic therapy initiated at a late time-point, but do not 
include other therapeutic strategies as used clinically, and see minimal changes 
in survival (Turnbull et al 2003).  Therefore these models mimic more of a local 
infection or SIRS phenotype rather than septic shock.  When long-term studies 
are performed using these models, molecular analyses are performed without 
functional analysis of muscle strength, therefore associations cannot be made. 
In addition to lack of therapeutic intervention in other models, many 
studies use the cecal ligation and puncture (CLP) surgical model of sepsis, which 
we believe is not appropriate for long-term studies.  Instead, we used the cecal 
slurry (CS) injection model to induce polymicrobial abdominal sepsis for multiple 
reasons: (i) mice that survive CLP-induced sepsis have a ligated cecum that may 
affect dietary habits and GI function, in addition to unresolved necrosis which 
may introduce variability in long-term physiological processes; (ii) cecum shape 
is often highly variable among older mice (Starr, Steele et al 2014), which causes 
variability in ligation site; (iii) the severity of sepsis can be more precisely and 
accurately controlled using this CS-model (by controlling the injection volumes) 
than CLP-model can control (by puncture size or number); (iv) the CS-injection 
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model does not require anesthesia and surgery, and thus is highly reproducible 
and a larger number of mice can be investigated in a shorter time.   
Therefore, currently existing models do not mimic the clinical situation, 
especially when experimental questions concern long-term outcomes of septic 
shock survivors.  With the lack of an ICU-like resuscitation protocol, and with the 
majority of current studies using the CLP model which introduces multiple 
concerns as noted above, progression in the field has been blunted despite 
recognition of muscle weakness as a clinical problem in sepsis survivors. 
 
1.4 Significance of using middle-aged animals 
 In addition to the limitations of current sepsis animal models discussed 
above, another shortcoming of the majority of studies is the lack of consideration 
for age of animals used.  Sepsis is a disease of the aged, where advanced age is 
an established risk factor for both incidence and mortality (Figure 1.5; Martin et 
al 2006; Elixhauser et al 2011; Angus et al 2001; Dombrovskiy et al 2007).  This 
age-associated susceptibility may be in part due to decreased immune function 
in the aged, including failed antigen processing and altered inflammatory 
responses including failed antigen processing by leukocytes (Pawelec et al 1998) 
and altered inflammatory cytokine expression (Miller et al 1996; Tateda et al 
2006; Martin et al 2006).  Further, age is associated with coagulation 
abnormalities (Starr & Saito 2014; Cohen et al 2003; Mari et al 1995).  The 
incidence rate for sepsis in the middle-aged (ages 45-64) is nearly four times 
higher than in younger adults  (ages 18-44) (Elixhauser et al 2011), and the 
incidence rate is increasing disproportionately with age compared to young 
adults (20.4% faster) (Martin et al 2006).   
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Figure 1.5.  Risk of sepsis incidence and mortality increase with 
advancing age.  Incidence rate (left abscissa) and case-fatality rates (right 
abscissa) for sepsis are adjusted and stratified by age deciles over a 24-year 
(from 1979-2002; >10 million adult sepsis patients) study period.  Data is 
represented as means ± SEM.  Martin et al. 2006. 
  
1.5 Study rationale 
1.5.1 Critical barrier to progress in the field 
 The scientific community acknowledges that sepsis-induced muscle 
weakness is a serious problem, especially as the population of sepsis survivors 
grows by > 1 million every year.  Muscle weakness during sepsis in humans and 
animal models, with special emphasis on atrophic mechanisms, has been 
studied extensively.  However, the scientific community lacks a severe animal 
model of sepsis that can be used to study chronic pathophysiologies; mild sepsis 
models do not exhibit chronic muscle weakness, whereas severe sepsis models 
cause early death of animals and thus prevent long-term studies.  The lack of an 
appropriate model has been a critical barrier to the identification of factors that 
are involved in muscle weakness after sepsis. This has greatly prevented 
progress in elucidating therapeutic targets to prevent and/or recover muscle 
strength in sepsis survivors and allow patients to return to normal productive 
lives. 
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1.5.2 Central hypothesis 
We hypothesized that if lethal sepsis was induced, and ICU-like 
therapeutic interventions were performed after development of bacteremia, then 
sepsis survivors with long-term muscle weakness would be achieved and then 
utilized to elucidate the underlying responsible mechanism(s). 
 
1.5.3 Specific aims 
In pursuit of this dissertation project, two specific aims were set: 
 
SPECIFIC AIM 1: To develop a clinically relevant non-lethal severe model of 
sepsis that results in chronic muscle weakness.  Under this aim, the protocol 
for preparation of cecal slurry (CS) was refined so that large batches could be 
frozen for long-term storage without reduced bacterial bioactivity (Chapter 2) 
which ensured efficiency and reproducibility in the later parts of this project.  The 
CS injection model of polymicrobial sepsis was then used in young animals for 
development of a novel delayed-intervention ICU-like aggressive resuscitation 
protocol which rescues the majority of animals from otherwise completely lethal 
sepsis (Chapter 3).  Third, this CS injection/ICU-like resuscitation protocol was 
adapted for middle-aged animals, and muscle strength was assessed in sepsis 
survivors two weeks later using ex vivo analysis (Chapter 4).   
 
SPECIFIC AIM 2: To characterize long-term muscle weakness in sepsis 
survivors on the sub-cellular level.  Under this aim, we first identified that 
myopathy, rather than atrophy or polyneuropathy, is responsible for post-sepsis 
muscle weakness in murine sepsis survivors (Chapter 4).  Next, skeletal muscle 
mitochondrial integrity was assessed by transmission electron microscopy, 
function was evaluated by respiration analysis and histochemical assays, and 
markers of oxidative damage were measured (Chapter 5).  The results of this aim 
indicate that sepsis-mediated changes in muscle quality rather than quantity are 
responsible for chronic muscle weakness in sepsis survivors.    
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CHAPTER 2 
Refinement of the Cecal Slurry Model of Experimental Sepsis 
 
2.1 Abstract 
 Sepsis is widely studied using laboratory animal models, most often using 
the cecal-ligation and puncture (CLP) surgical model of abdominal sepsis.  
Although it is considered the gold standard model for sepsis research, it may not 
be preferable for experiments comparing animals of different size or under 
different dietary regiments.  By comparing cecum size, shape, and cecal content 
characteristics in mice under different experimental conditions (aging, diabetes, 
pancreatitis), we show that cecum variability could be problematic for some CLP 
experiments.  Additionally, the CLP model of sepsis is not appropriate for long-
term studies on sepsis survivors due to ongoing necrosis of the ligated cecum 
which is not controlled for as an experimental variable.  The cecal slurry (CS) 
injection model, in which the cecal contents of a laboratory animal are injected 
intraperitoneally to other animals, is an alternative method for inducing 
polymicrobial sepsis; however under conventional protocols the CS must be 
freshly prepared which is a major disadvantage with respect to reproducibility 
and convenience.  The objective of this study was to develop an improved CS 
preparation protocol that allows for long-term storage of CS with reproducible 
results upon injection.  Using our new CS preparation protocol we found that 
bacterial viability is maintained for at least 6 months when the CS is prepared in 
15% glycerol-PBS and stored at -80°C.  To test sepsis-inducing efficacy of stored 
CS stocks, various amounts of CS were injected to young (4-6 months old), 
middle-aged (12-14 months old), and aged (24-26 months old) male C57BL/6 
mice. Dose- and age-dependent mortality was observed with high reproducibility.  
Circulating bacteria levels strongly correlated with mortality suggesting an 
infection-mediated death.  Further, injection with heat-inactivated CS resulted in 
acute hypothermia without mortality, indicating that CS-mediated death is not due 
to endotoxic shock. This new CS preparation protocol results in CS stocks which 
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are durable for freezing preservation without loss of bacterial viability, allowing 
experiments to be performed more conveniently and with higher reproducibility 
than before. 
 
2.2 Introduction 
Among various types of animal models for sepsis research, cecal ligation 
and puncture (CLP) is one of the most frequently used procedures to induce 
experimental sepsis in laboratory animals such as mice and rats (Dejager et al 
2011, Wichterman et al 1980, Hubbard et al 2005). Under the CLP model, 
polymicrobial peritonitis is induced in anesthetized animals by surgical ligation of 
the cecum followed by needle puncture to secrete cecal contents into the 
abdominal cavity.  The CLP model has been preferred by many investigators 
who study sepsis using laboratory animals because it is a relatively simple 
surgical procedure and closely mimics the clinical course of intra-abdominal 
sepsis (Dejager et al 2011).  
However, the severity of CLP-induced sepsis is highly dependent on the 
degree of infection which can be influenced by volume, rapidity, and duration of 
cecal content released into the abdomen, and by the bacterial flora present in the 
cecum.  Therefore, despite its popularity, CLP may not be preferable for certain 
experiments including those investigating animals with different cecum size, 
shape, or bacterial flora. This concern may apply for studies that compare 
severity of sepsis among animals with different body size (e.g. neonatal mice or 
mutant dwarf mice), under different diet regimens (e.g. liquid diet, high fat diet, or 
diet restriction), different gastrointestinal conditions (e.g. neonatal or aged 
animals or animals with gastrointestinal pathology), or increased sensitivity to 
surgery (e.g. aged animals or animals with deficient wound-healing capability).   
Additionally, the CLP model is not appropriate for long-term studies on 
sepsis survivors.  Animals that survive CLP-induced sepsis have a ligated cecum 
that may affect dietary behaviors and GI function.  Further, the ligated cecum 
undergoes necrosis which likely potentiates an inflammatory response.  Although 
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control animals undergo a sham operation, the cecal ligation is rarely performed.  
Therefore, CLP sepsis survivors often have unresolved necrosis and ongoing 
inflammation that is not controlled for among groups, making it impossible to 
determine if any difference in phenotype across groups is due to sepsis itself or 
due to the ongoing influence of the ligated cecum. 
 In cases when CLP is not preferable, intraperitoneal injection of cecal 
slurry (CS) is an alternative method.  In the CS model, contents from the cecum 
of donor animal(s) are suspended in liquid form and injected into the abdominal 
cavity of other animals to induce polymicrobial sepsis (Gentile et al 2014, Wynn 
et al 2007, Shrum et al 2014, Gentile et al 2014, Lang et al 1983). The CS model 
of sepsis has been preferred by a limited number of investigators, particularly 
those who study sepsis in neonatal mice. However, one prominent disadvantage 
of the CS model is that the currently accepted protocol for CS preparation with 
5% dextrose in water (D5W) does not allow for long-term storage, and thus the 
CS has to be freshly prepared each time an experiment is performed (Sam et al 
1997). This can lead to significant variability from experiment to experiment. 
Thus, the first set of experiments under this project was aimed at circumventing 
this problem.  We developed a new CS preparation procedure that allows for the 
long-term storage of CS stocks without loss of bacterial viability. In addition, we 
validated survival rates of mice at different ages using stored CS prepared with 
this new protocol.       
 
2.3 Experimental approach 
 To evaluate potential differences in cecum characteristics across 
experimental models, cecums from young (4-6 month-old) healthy mice were 
compared to those from animals with chronic pancreatitis, type I diabetes, or 
aged (24-26 month-old) animals.   To induce chronic pancreatitis in mice, 
recurrent acute pancreatitis was induced in young mice (6-months old) by a 
procedure modified from our previous protocol for acute pancreatitis (Okamura et 
al. 2012). Each mouse received intraperitoneal (i.p.) injection with either 
physiological saline (control) or caerulein at a dose of 50 μg/kg body weight, 6-
21 
times hourly, 3 days per week for 9 weeks.  To induce diabetes, fasted mice 
received streptozotocin at a dose of 45 mg/kg body weight, i.p. once daily for 5 
consecutive days. Control mice received no injection.   
For cecum analysis, at sacrifice, ceca were dissected from mice using 
sterile instruments. Each cecum was placed in a plastic container, weighed, and 
photographed. The contents of each cecum were collected using sterile forceps 
and spatula, weighed (wet weight), and dried in an oven at 60°C for 48h (dry 
weight). A wet/dry ratio was calculated for the contents of each cecum. 
To assess the aerobic cecal bacteria, immediately after collection, cecal 
contents from young and aged mice were suspended in sterile water at a 
concentration of 5 mg/mL. The resulting suspension was mixed well and 50 μL 
was spread onto multiple agar plates containing 3.7% w/v brain-heart infusion 
and 0.15% w/v agar with aztreonam for Gram-positive bacteria selection (Wood 
et al 1993), penicillin G for Gram-negative selection, or without antibiotics for total 
aerobic bacteria quantification. 
  
2.4 Results 
2.4.1 Cecum size, shape, and cecal content consistency varies widely among 
different experimental conditions 
To show that under some experimental conditions the CLP model of 
sepsis is not ideal, we compared cecum size, shape, and cecal content 
consistency in various animal models including diabetes, chronic pancreatitis, 
and aging.  Type 1 diabetes was induced by multiple low dose streptozotocin 
(STZ) injection model (confirmed by hyperglycemia), and ceca were dissected 
from mice at sacrifice.  Cecal content wet weight were not different between the 
two groups (Figure 2.1 A), but cecal content wet/dry ratio (Figure 2.1 B) showed 
a significant difference indicating that cecal matter within the cecum of diabetic 
mice has a different consistency than normal mice. This could complicate CLP-
induced sepsis because the watery cecal content of diabetic mice may leak into 
the abdomen from the puncture site much more rapidly than that of control mice. 
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Figure 2.1.  Abnormal consistency of cecal contents in diabetic mice.  
Ceca and cecal contents were collected from non-treated control and 
streptozotocin (STZ)-induced diabetic mice.  Wet weight of cecal contents (A) 
and wet/dry weight ratio of cecal contents (B) were measured (n=5 per group).  
Figure adapted from Starr, Steele et al. 2014 used under international license 
CC BY 4.0. 
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 Chronic pancreatitis was induced by repeated bouts of acute pancreatitis 
using caerulein injection and ceca were dissected from mice at sacrifice. 
Macroscopically, the ceca of mice with chronic pancreatitis appeared enlarged 
and fuller than that of control mice (Figure 2.2 A). Cecal content wet weight was 
significantly different (p<0.001) between the two groups (Figure 2.2 B) indicating 
that mice with chronic pancreatitis have more fecal matter in their cecum. The 
wet/dry ratio of cecal content between control mice and mice with chronic 
pancreatitis was not significantly different (Figure 2.2 C).  Whole cecum weight 
was significantly different (Figure 2.2 D).  These findings indicate that while stool 
consistency is similar, the enlarged ceca of mice with chronic pancreatitis could 
be problematic when determining which portion of the cecum to ligate during CLP 
procedure.   
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Figure 2.2.  Mice with chronic pancreatitis have enlarged ceca.  
Macroscopic images (A), wet weight of cecal contents (B), wet/dry weight ratio 
of cecal contents (C), and whole cecum weight (D) from mice with caerulein-
induced chronic pancreatitis and saline-injected control mice (n=5 per group).  
Figure adapted from Starr, Steele et al. 2014 used under international license 
CC BY 4.0. 
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Figure 2.3.  Cecal shape is highly variable in aged mice.  Macroscopic 
images (A), wet weight of cecal contents (B), wet/dry weight ratio of cecal 
contents (C), and whole cecum weight (D) from mice with caerulein-induced 
chronic pancreatitis and saline-injected control mice (n=5 per group).  Adapted 
from Starr, Steele et al. 2014 used under international license CC BY 4.0. 
 
 
 
 We further compared cecum size, shape, cecal content consistency, and 
bacterial flora in young (4-6 month-old) versus aged (24-26 month-old) mice.  
Ceca were dissected using sterile instruments from young and aged mice at 
sacrifice.  Macroscopically, the ceca of young mice appear uniform in size and 
shape, while the ceca size and shape are more variable among aged mice 
(Figure 2.3 A).  Despite different cecum shape and significantly different body 
weight in this set of young and aged mice (27.8 ± 2.2 and 36.5 ± 1.7 respectively, 
p<0.001), cecum wet weight, cecal content wet/dry ratio, and whole cecum 
weight did not show differences between the age groups (Figure 2.3 B-D).   
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Figure 2.4.  Cecum bacterial flora are similar among the young and aged.  
Cecal contents from young and aged mice were suspended in sterile water 
and spread onto agar plates without antibiotics, with aztreonam to select for 
Gram-positive bacteria, or with Penicillin G to select for the majority of Gram-
negative bacteria.  Data represent the mean ± standard deviation, n=5 for 
each group.  Figure adapted from Starr, Steele et al. 2014 used under 
international license CC BY 4.0. 
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A small portion (~100 mg) of the cecal content from each mouse cecum 
was taken under sterile conditions for aerobic bacterial analysis. Fecal material 
was dissolved in sterile water at a concentration of 5 mg/mL and spread onto 
agar plates with penicillin G to select for Gram-negative bacteria, Aztreonam to 
select for Gram-positive bacteria, or without any antibiotics for total aerobic 
bacterial quantification.  No significant differences were found in aerobic bacteria 
colony formation for total bacteria, or when selecting for Gram-positive or Gram-
negative bacteria (Figure 2.4).  Collectively, these data indicate that while cecum 
shape in aged mice are more variable and differ from that of young mice, cecal 
content in terms of weight and bacterial flora are highly similar.     
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2.4.2 Cecal slurry bacteria remain bioactive after long-term storage when 
prepared using a refined protocol 
 Our objective was to establish a cecal slurry preparation protocol that 
eliminates the prior necessity of preparing the slurry fresh the day of sepsis 
induction.  Therefore, we refined the protocol so that cecal contents are 
suspended in a glycerol solution to allow for freezing of the slurry-containing 
bacteria (Figure 7.1).  Four-month-old C57BL/6 mice were sacrificed by cervical 
dislocation and the whole cecum was dissected from each mouse. The cecal 
contents were collected using sterile forceps and spatula, and the cecal contents 
were combined, weighed, and mixed with sterile water at a ratio of 0.5 mL of 
water to100-mg of cecal content. This cecal slurry was sequentially filtered 
through sterile meshes (860, 190, and 70 mm. The filtered slurry was then mixed 
with an equal volume of 30% glycerol in phosphate buffered saline (PBS), 
resulting in a final CS stock solution in 15% glycerol. While continuously stirring 
on a plate with a magnetic stir bar, the CS stock was dispensed into cryovials. 
To determine whether bacterial viability could be maintained in stored CS 
samples, CS stocks were prepared in 15% glycerol buffer and stored in aliquots 
at 4, -20, and -80°C. One aliquot was immediately diluted and spread onto agar 
plates to determine colony forming ability. One and six weeks after preparation, 
an aliquot of CS stock from each storage condition was thawed and colony 
forming ability determined by spreading on agar plates as was done for the 
freshly prepared solution. Bacterial viability was maintained only in the stocks 
stored at -80°C (Figure 2.5 A). Significant loss of viability was observed in the 
CS stocks at both one and six weeks following storage at -20 and 4°C (Figure 
2.5 A). Similar results were obtained when CS was stored in 5% and 10% 
glycerol buffer with the colony forming ability maintaining 100% of original 
capability after cryopreservation at -80°C for 6 weeks (data not shown). 
Additional CS stocks stored in 15% glycerol/PBS at -80°C were kept for up to six 
months with bacterial viability being tested periodically. After 6- months of 
storage at -80 °C, bacterial viability was maintained at 99.5% of the freshly 
prepared CS (Figure 2.5 B). 
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Figure 2.5.  Cecal slurry bacteria maintain bioactivity following long-term 
storage at -80°C. Cecal contents were prepared in 15% glycerol and CS 
samples were stored at -80, -20, and 4°C.  Colony formation unit (CFU) was 
compared one and six weeks later for all storage conditions (A) and up to 6-
months later for samples stored at -80°C (B). Data represent the mean ± SD.  
Figure adapted from Starr, Steele et al. 2014 used under international license 
CC BY 4.0. 
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2.4.3 CS-induced sepsis reproduces age-dependent sepsis severity and mortality 
 To test the efficacy of stored CS stocks at inducing sepsis, three different 
age groups of mice were intraperitoneally injected with standardized doses of CS 
and survival monitored for at least 10 days.  As shown in Figure 2.6 A, 100uL of 
CS was non-lethal to young and middle-aged mice but caused 50% lethality in 
aged mice. By increasing the dose of CS from 100μL to 150uL, survival in aged 
mice was reduced to 38%, survival in middle-aged mice was reduced to 67%, 
and young mice maintained 100% survival (Figure 2.6 B).  
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Figure 2.6.  CS-induced sepsis reproduces age-dependent mortality.  
Young, middle-aged, and aged C57BL/6 mice were injected with either (A) 
100µL or (B) 150µL CS and survival monitored for eight days.  Figure adapted 
from Starr, Steele et al. 2014 used under international license CC BY 4.0. 
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2.4.4 The severity of CS-induced bacteremia is associated with mortality 
To assess the degree of bacteremia in CS-injected mice, blood was 
collected from the tail vein of mice and bacterial colony formation units assessed 
by spreading onto agar plates.  Blood was collected at 12, 24, and/or 48h and the 
timepoint with the highest CFU was used.  After monitoring survival for 10-15 
days, blood CFU was compared between survivors and non-survivors.  
Circulating bacteria CFU correlated with mortality in various ages of mice injected 
with 100uL of CS (Figure 2.7 A) or 200uL of CS (Figure 2.7 B).  
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Figure 2.7.  Amount of circulating bacteria correlates with mortality. (A) 
Blood was taken from the tail vein of young, middle-aged, and aged mice 12, 
24, or 48h after injection with 150µL CS and colony formation units (CFU) 
assessed by spreading on agar plates. After fifteen days, data from mice 
which survived or died were separated into two groups and CFU compared. 
(B) Blood was taken from the tail vein of young mice 24h after injection with 
200 or 400µL CS and CFU assessed by spreading on agar plates. After ten 
days, data from mice which survived or died were separated into two groups 
and CFU compared. Each symbol represents data from a single animal.  
Figure adapted from Starr, Steele et al. 2014 used under international license 
CC BY 4.0. 
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2.4.5 CS-induced death is not mediated by endotoxemia 
 To eliminate the possibility that death due to CS-induced sepsis occurs by 
endotoxic shock from bolus bacterial injection, an experiment was performed in 
which CS was heat-inactivated to kill bacteria and then injected to mice (Figure 
2.8). The same volume of vehicle (15% glycerol) and untreated CS were injected 
in parallel. Vehicle injection induced a very mild acute drop in body temperature 
of approximately 1.5°C which returned to baseline within 12h similar to our 
previous observation using saline as a vehicle (Saito et al 2003).  Both heat-
inactivated CS and untreated CS induced profound acute hypothermia with body 
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Figure 2.8.  Injection of heat-inactivated cecal slurry (CS) induces 
endotoxemia but not mortality. Mice (13-month-old) were injected with 
200µL of untreated CS (in 15% glycerol/PBS), heat-inactivated (72°C for 15 
minutes) CS, or vehicle (15% glycerol), and the rectal body temperatures 
monitored for several days.  CS injected mice died within 48 hours, while no 
mortality was observed in other groups. Data represent the mean ± standard 
deviation, n=3 for each group.  Figure adapted from Starr, Steele et al. 2014 
used under international license CC BY 4.0. 
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temperature falling to 32°C within 3h after injection. Hypothermia was sustained 
at 32°C in heat inactivated-CS injected mice for 24h at which point the mice 
began to normalize and all survived, while the untreated CS-injected mice 
continued to exhibit profound and worsening hypothermia and eventually died.  
These results suggest that the CS model of sepsis induces non-lethal temporal 
endotoxemia, but that prolonged illness and death is due to infection. 
 
 
 
 
 
 
31 
2.5 Discussion 
While performing small animal surgeries or harvesting organs from mice 
over the last several years (Okamura et al 2012; Saito et al 2003; Starr et al 
2012; Starr et al 2009; Starr et al 2010; Starr et al 2011), our group noticed that 
mice can have highly variable cecum shape and size, and we continuously 
hypothesized that this variability may affect the result of CLP-induced sepsis.  
Due to these observations we felt that CLP may not always be an appropriate 
animal model for inducing experimental sepsis. While others have acknowledged 
potential problems of the CLP model regarding variability in technique (Dejager 
et al 2011; Sam et al 1997; Buras et al 2005; Zanotti-Cavazzoni & Goldfarb 2009; 
Rittirsch et al 2009), variability in animals used for experiments has been largely 
ignored. Certainly the benefits of using the CLP model may outweigh the 
limitations compared to other experimental models of sepsis (Dejager et al 2011); 
however, several characteristics of the animals used in each study design should 
be carefully considered before assuming that CLP is the ideal model for every 
experiment. We have shown that the size and shape of the cecum, and/or the 
nature of cecal contents can be significantly altered by aging or in certain disease 
conditions (e.g. insufficient digestion in chronic pancreatitis or excessive water 
consumption in diabetes mellitus). Under these conditions, results from CLP-
induced sepsis would be completely misinterpreted, and use of the CS model is a 
good alternative.  For example, CLP performed to compare drug efficacy in mice 
of the same strain and body size where a subset of the mice receive a drug and 
another subset do not would be a perfectly appropriate CLP-experiment. While 
comparing the effects of CLP-sepsis in mice of significantly different body/cecum 
size (e.g. juvenile vs mature adult, wild-type vs some transgenics), or with 
significantly different diets or water consumption rates could be problematic due 
to the nature of the CLP technique.  
 As aging is one of our research group’s primary interests, we took 
additional effort to characterize the cecum and cecal contents from young versus 
aged mice.  While we did not observe any statistically significant differences in 
whole cecum weight, or cecal content weight and wet/dry ratio between the ages 
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of mice used in this study (4-6 month and 24-26 month), we did notice 
considerable differences in cecum shape.  As can be seen in Figures 2.2 and 
2.3, cecum shape can be highly variable, particularly at the distal end (where 
ligation typically occurs). This variability can alter CLP-sepsis induction since 
ligation is performed at a designated length, and the shape of the cecum at this 
location may vary from animal to animal.  Our data suggest that if appropriate 
surgical technique is applied (taking into account variable size and shape of 
cecum), CLP-induced sepsis likely elicits a similar bacterial infection in young 
and aged mice. Indeed we and others have shown an age-associated increase in 
mortality after CLP-induced sepsis (Saito et al 2003; Turnbull et al 2003), similar 
to the current CS study. However, due to sensitivity of aged mice to surgical 
manipulation (Rosczyk et al 2008), CLP may cause other significant responses in 
addition to the effect of infection.  After performing CLP on aged mice, we have 
also noted multiple times that the large epididymal fat pads of aged mice can 
adhere to the cecal puncture injury and contain the source of infection which 
would abrogate CLP-induced sepsis. In our experience this occurred when CLP 
was performed on older ages of mice (10-26 months of age) with more intra-
abdominal adipose tissue, but not in lean young mice (2-4 months of age) with 
minimal amounts of abdominal fat. This observation is similar to what physicians 
have observed clinically when the omentum adheres to sites of injury within the 
abdomen (Ambroze et al 1991).  Though ideal for survival, this occurrence 
causes a high degree in variability of response depending on whether and when 
the fat adhered to the cecal puncture in experimental animals. 
 In addition to other advantages, the use of the CS model is also valuable 
in experiments which require large numbers of animals. Experimental sepsis can 
be easily induced in a large number of animals in a short period of time by CS 
injection, as opposed to CLP which requires a significant amount of time for 
anesthesia and surgery on each animal.  Likewise, another benefit of the CS 
model is that surgery is not required, thus potential differences among animal 
groups in response to surgery or wound healing would be alleviated. 
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 Also important to note, especially in respect to this dissertation work, is 
that the CS injection model of polymicrobial sepsis is more appropriate when the 
experimental question centers on evaluating the post-sepsis condition.  In the 
CLP model, cecal ligation is performed in animals given sepsis, however the non-
sepsis control animals receive a sham operation without a cecal ligation.  
Therefore, in long-term studies on sepsis survivors, the necrotic cecum likely 
stimulates a proinflammatory state, that may be responsible for any observed 
phenotype, as opposed to sepsis itself.  Therefore, we believe the CS injection 
model is most applicable for these types of studies.  
 Despite some reports indicating the contrary (Cross et al 1993), CS is an 
infectious model. Other groups have supported this notion with evidence of 
bacterial colonization, abscess formation, systemic inflammation, and spleen 
alterations characteristic of infection (Wynn et al 2007).  We further confirmed 
this using our new CS preparation protocol since analyses of bacteria in the 
blood in our present study show a strong correlation with mortality.  Further, 
levels of circulating bacteria which exceed the amount of bacteria administered 
provide evidence of replication. Heat-inactivation of a lethal dose of CS resulted 
in no mortality suggesting that CS-mediated death results from the infectious 
component of CS rather than endotoxic shock due to bolus injection.  Studies in 
rats also showed similarity of the CS injection model with human sepsis in that it 
induces such physiological changes as hypotension, elevated lactate, leucopenia 
and leukocytosis, and formation of abdominal abscesses (Lang et al 1983; Sam 
et al 1997).   
 In the preparation of our CS stocks for injection, the cecal contents were 
suspended in PBS buffer with a final concentration of 15% glycerol before 
cryopreservation. We used 15% glycerol because it is commonly used for 
cryopreservation of bacteria (Maniatis et al 1982).  Fecal transplantation studies 
show 10% glycerol in saline as a suitable suspension buffer for cryopreservation 
and future administration of fecal matter to patients without loss of efficacy in 
patient outcome (Hamilton et al 2012). Recently, we also confirmed that CS 
stocks can be stored in 5 or 10% glycerol without loss of viability for at least 6 
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weeks, suggesting that suspending cecal contents in glycerol to a final 
concentration of at least 5% may also be suitable for CS cryopreservation; 
however, we have not tested survival curves with these preparations.   
 A limitation of this study is that we did not fully characterize the bacteria in 
the CS stocks.  We do not know what proportion of aerobic or anaerobic bacteria 
can survive cryopreservation thus the bacteria remaining in the CS stock after 
freezing and thawing may not be entirely representative of that derived from 
freshly injected CS or CLP.  However, this does not differ from current CS or CLP 
studies in which the bacterial flora of mice used is not routinely analyzed and can 
vary from strain to strain and by vendor (Hufeldt et al 2010; Campbell et al 2012; 
Hildebrand et al 2013).  Preparation of CS with our new protocol induces 
polymicrobial sepsis with organisms endogenous to the host and causes both 
acute endotoxemia and prolonged bacteremia with the latter being primarily 
responsible for mortality.   
 
2.6 Conclusions 
This new cecal slurry (CS) preparation protocol using glycerol/PBS is 
durable for freezing preservation at -80°C without loss of bacterial viability, 
allowing us to perform polymicrobial sepsis experiments more conveniently and 
with higher reproducibility than conventional methods. Injection of mice with 
cryopreserved CS can reproducibly induce both mild and severe sepsis with 
mortality rates dependent on both injection dose and animal age. Further, CS-
induced mortality is due to bacterial infection, not acute endotoxic shock since (1) 
heat-treatment of an otherwise lethal dose of CS did not kill the mice, and (2) 
there was a strong correlation between mortality and blood bacteria counts. 
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Note: Portions of this chapter were adapted and reprinted under 
international license CC BY 4.0: Starr ME, Steele AM, Saito M, Hacker BJ, 
Evers BM, Saito H (2014).  A New Cecal Slurry Preparation Protocol with 
Improved Long-Term Reproducibility for Animal Models of Sepsis.  PLoS ONE 
2014; 9(12): e115705. 
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CHAPTER 3 
Development of a Late-Intervention ICU-Like Resuscitation Model of Sepsis 
Which Results in High Survival 
 
3.1 Abstract 
 Current animal models of sepsis often incorporate antibiotics to be 
consistent with clinical standards for treatment of patients in the ICU.  However, 
such experimental intervention is commonly initiated very early after infectious 
insult, which likely blunts the progression of systemic inflammation and 
downstream pathology.  The objective of this study was to establish an animal 
model of sepsis with delayed therapeutic intervention, allowing a longer disease 
course and downstream pathology, but still resulting in a high survival rate.  
Severe lethal abdominal infection was initiated in young adult (17-18 week-old) 
C57BL/6 mice by cecal slurry (CS) injection.  When initiated early (1 or 6 hours 
post-CS injection), antibiotic treatment (imipenem, 1.5mg/mouse i.p., twice/day 
for 5 days) rescued the majority of mice; however, few of these mice showed 
evidence of bacteremia, cytokinemia, or organ injury. When antibiotic treatment 
was delayed until late time-points (12 or 24 hours post-CS injection) the majority 
of animals did not survive beyond 48 hours.  When fluid resuscitation 
(physiological saline, s.c.) was performed in combination with antibiotic treatment 
beginning at these late time-points, the majority of mice survived (75%) and 
showed bacteremia, cytokinemia, organ dysfunction, and prolonged body weight 
loss (<90% for 4 weeks).   We recommend that this new repeated combination 
treatment with antibiotics and fluid resuscitation be initiated at a late time point 
after bacteremia becomes evident because this model more closely mimics the 
downstream pathological characteristics of severe clinical sepsis yet maintains a 
high survival rate.  This model would be advantageous for studies on severe 
sepsis and post intensive care illness. 
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3.2 Introduction 
 As the sepsis incidence rate continues to grow and the mortality rate in 
patients with sepsis and septic shock remains high, the need for a highly 
translational animal model has become of upmost importance.  In recent years, 
the applicability of animal models for sepsis studies has come under question, 
spurred by the Seok et al. (2013) report that genomic responses to inflammatory 
diseases show little to no correlation among mice and humans.  This study was 
highly publicized and sparked unfortunate criticism of biomedical research 
despite having many study limitations such as disregard of sex, age, strain, or 
disease severity in their data analysis (Osuchowski et al 2014).  Takao et al. 
recently reported that after reanalyzing the same data sets taking into account 
disease conditions and utilizing more conventional statistical methods the 
conclusion was reversed: gene expression patterns are highly similar among 
mice and humans (Takao & Miyakawa 2015).  Murine models of sepsis are in 
fact powerful tools for biomedical research, but come with an urgent need to 
understand the various strengths and weaknesses of different models which 
must be weighed in the context of the research question being posed (Deitch 
2005).  The choice of model is a critical decision that heavily influences the 
relevance of the experimental outcomes in respect to clinical translation ability 
(Deitch 1998).   
To more closely mimic the clinical situation, antibiotic therapy is often 
included in infectious models (e.g. Turnbull et al 2003; Newcomb et al 1998; Xiao 
& Remick 2005; Marques et al 2013); however the timing of therapeutic 
intervention is largely inconsistent due to many unresolved questions in the field 
regarding how animal models relate to clinical sepsis.  Most of these studies 
administer antibiotics immediately or within a few hours after infectious insult. 
The time-course of sepsis is accelerated in animals compared to patients, 
making early intervention with antibiotic therapy a plausible therapeutic strategy, 
but patients are seldom treated in this narrow window (Turnbull et al 2004).    
We hypothesized that therapeutic intervention initiated prior to the 
development of bacteremia would halt the progression from local to systemic 
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infection, thus preventing the development of severe sepsis and downstream 
pathology.  To test this hypothesis, we first assessed the kinetics of bacteremia 
following infectious insult in adult mice using the cecal slurry model of abdominal 
sepsis.  Further, we methodically determined the most appropriate timing and 
combination of therapies which when initiated at late time-points allows the 
progression of local to systemic infection, maintains sepsis pathophysiology, and 
still results in high survival. Here we present a new repeated combination 
treatment procedure initiated at a late time point which would be useful for 
studies on severe sepsis and post sepsis dysfunctions. 
 
3.3 Experimental approach 
 The objective of the first experiment was to determine the kinetics of 
bacteremia development following cecal slurry (CS) injection, animals were 
administered a lethal dose (i.p.) and blood from the tail vein was cultured 1, 6, 
and 12 hours later.  Next, we began our studies on therapeutic intervention.  For 
antibiotic treatment, we used imipenem as it is a broad-spectrum antibiotic with 
potent capabilities for treating infection and is widely used in animal models of 
sepsis (Newcomb et al 1998; Coopersmith et al 2003; Marques et al 2013).  
Imipenem (IPM) was reconstituted in sterile physiological saline for a final 
concentration of 0.005mg/mL.  The dose of IPM equivalent to the maximum dose 
administered to patients in hospitals was determined to be 1.5 mg.  Assuming 
young lean mice have 2-mL of blood, the final concentration of IPM in the blood 
(0.75 mg/mL) was used for in vitro bacteria culture and confirmed that CS 
bacteria (up to 500 CFU/mL) were unable to grow in the presence of IPM, even 
at 100-times diluted concentrations (Figure 3.1). IPM was aliquoted and frozen 
at -20°C for up to 1 week (under these storage conditions IPM maintained 95% 
efficacy).   
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Figure 3.1.  Imipenem prevents the growth of cecal slurry-containing 
bacteria at physiological concentrations.  The growth of cecal slurry 
bacteria in liquid culture was assessed by optical density (OD600) 
measurement 24 hours after inoculation of either 200 or 500 CFU in the 
absence (0mg/mL; negative control) or presence (0.75, 0.075, and 0.0075 
mg/mL) of imipenem (IPM), where 0.75 mg/mL represents the approximate 
concentration in the blood.  Figure adapted from supplemental data shown in 
Steele et al. 2017.   
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Imipenem was administered (1.5 mg per mouse) beginning 1, 6, and 12 
hours after CS injection.  The early intervention groups received another 
treatment 12 hours post-CS injection, and all groups then received treatments 
every 12 hours for 5 days or until death. Survival, body weight, and body 
temperature were monitored for at least 10 days.   
  In some experiments, fluid resuscitation (700µL, physiological saline, s.c.) 
was administered alone or in addition to the 300µL of antibiotics beginning at 12 
or 24 hours after CS injection.  Antibiotics and fluids were administered twice 
daily.  Antibiotic therapy was continued for 5 days, and fluid resuscitation was 
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continued until body temperature recovered to at least 35.0°C.  Further details 
are given in Section 7.6. 
 The bacterial load of animals injected with CS was evaluated before and 
during therapeutic intervention by culturing small blood samples obtained from 
micropuncture of the tail vein.  A portion of this blood sample was also cultured 
on agar plates containing antibiotics (2 mg/mL IPM), and the remaining half of 
the blood sample was spread on plates without antibiotics.  Plates were 
incubated at 37°C for 24 ± 2 hours, colonies were counted, and CFU was 
calculated.  Further details are provided in Section 7.5. 
 To assess severity of sepsis in relation to timing of therapeutic 
intervention, cytokinemia and markers of organ injury were evaluated.  For this 
experiment, animals were injected with either CS or vehicle (10% glycerol-PBS).  
The animals which received CS injection were subdivided into four groups: non-
resuscitated, 1h antibiotics, 6h antibiotics, and 12h antibiotics with fluid 
resuscitation.  All animals were euthanized 24 hours after CS or vehicle injection 
at which time plasma samples were obtained and stored at -80°C until 
biochemical assay were performed.  Interleukin-6 (IL-6), IL-10, IL-1β, and TNF-α 
levels were quantified (further details are given in Section 7.7).  Lung injury was 
evaluated through histological assessment and blinded scoring, and liver injury 
was evaluated by quantification of alanine aminotransferase (ALT) using a 
commercially available kit (further details in Section 7.8).   
  
3.4 Results 
3.4.1 The majority of animals cannot be rescued by delayed antibiotic treatment.  
First, we determined the kinetics of bacteremia in adult mice after CS-
mediated severe infection.  Severe infection was initiated by administration of a 
minimum lethal dose (LD100) of CS (500µL) and no therapeutic intervention was 
performed. Circulating bacteria was assessed 1, 6, and 12 hours after CS 
injection.  Of the 8 animals assessed, only 2 (25%) had circulating bacteria by 1 
hour, which increased to 4 (50%) by 6 hours, whereas all 8 (100%) animals had 
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bacteremia by the 12-hour time-point (Figure 3.2 A).  Based on these data, we 
defined “early intervention” time-points as ≤6 hours after CS injection at which 
time bacteremia is not always confirmed, and alternatively “late intervention” 
time-points as ≥12 hours after CS injection when 100% of animals have 
circulating bacteria.   
 Next, we investigated whether mice can be rescued from lethal sepsis if 
antibiotic therapy is initiated after blood bacteria became detectable in all 
animals.  The potent broad-spectrum antibiotic imipenem (1.5mg/mouse i.p.) was 
administered to mice beginning at late time-points (12 and 24 hours after CS 
injection) and the treatment was repeated twice daily for 5 days.   As a 
comparison, some mice also received antibiotic treatment beginning at early 
time-points (1 and 6 hours after CS injection).  A significant improvement in 
survival (80%, p<0.05 compared with no antibiotics group) was observed when 
antibiotic treatment was begun 1 hour after CS injection, and the majority of 
animals (60%) were also rescued when antibiotics were initiated at the 6-hour 
time-point.  However, only 33% (2 of 6) of animals were rescued when initiation 
of antibiotic treatment was delayed to 12 hours, and no animals survived when 
delayed further to 24 hours (n=5; Figure 3.2 B).  Important to note, the blood 
bacteria of moribund mice showed no resistance to the antibiotic.  Early 
intervention (starting at 1 and 6 hours) resulted in rapid recovery of body 
temperature (35.7± 2.3, 36.0 ± 1.9°C respectively) within 48 hours, whereas mice 
with late intervention developed sustained hypothermia (30.4±2.7°C at 48 hours) 
indicating that late intervention allows for a prolonged disease time-course 
(Figure 3.2 C).  Taken together, bacteremia does not develop in all mice until 12 
hours after CS injection and therefore late therapeutic intervention should be 
initiated at this time or later.  However, antibiotic treatment alone cannot rescue 
the majority of mice if delayed until these late time-points.   
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Figure 3.2 Survival rate and disease severity correlate with time of 
intervention after CS injection.  All mice were given a minimum lethal dose 
of cecal slurry (CS).  (A) Blood bacteria load was assessed 1, 6, and 12 hours 
after CS injection in animals (n=8) which did not receive therapeutic 
intervention.  (B-C) In another experiment, animals received antibiotic 
treatment (imipenem, IPM; 1.5mg i.p.) beginning 1, 6, 12, or 24 hours after CS 
injection.  Antibiotics were continued twice daily for five days (n=5-6 per 
group).  (B) Survival (star notates p<0.05 compared to no-antibiotics group) 
and (C) body temperature were monitored.  Data represent mean ± standard 
deviation.  Figure adapted from Steele et al. 2017. 
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3.4.2 Late therapeutic intervention with a combination of antibiotics and fluid 
resuscitation rescues the majority of animals 
We aimed to elucidate a therapeutic protocol which could be initiated after 
development of bacteremia and still achieve a high survival rate.  Antibiotic 
treatment alone (i.p.), fluid resuscitation alone (s.c.), or a combination of both 
were administered to septic mice beginning 12 hours after CS injection (500 μL) 
and continued twice daily for 5 days.  Without therapeutic intervention, 100% (5 
out of 5) mortality was observed by 48 hours confirming our earlier results shown 
in Figure 3.2 B.  Neither antibiotic therapy nor fluid resuscitation alone could 
rescue a significant number of animals (2 out of 7 and 1 out of 8, respectively).  
Conversely, combination treatment with antibiotics and fluid resuscitation when 
initiated 12 hours after CS injection resulted in 75% (6 out of 8) survival rate 
(Figure 3.3 A).  Late intervention with this combination therapeutic strategy 
resulted in significantly increased body temperature 12 hours after the first 
treatment (i.e. 24 hours after CS injection; p<0.01 compared to no-intervention 
group) although body temperature did not fully recover until 48 hours after CS 
injection (36 hours after therapeutic intervention; 36.1±1.3°C; Figure 3.3 B).  
Assessment of blood bacteria load 12 hours after CS injection confirmed that 
bacteremia had developed in all mice before therapeutic treatment was initiated.  
After 3 treatments with antibiotics and fluid resuscitation (administered every 12 
hours), bacteria load was significantly reduced and was completely resolved in all 
animals after 7 treatments (96 hours after CS injection; Figure 3.3 C).  
Further, because mice with sepsis tend to develop hypoglycemia, we 
tested the effects of glucose control by administering 1-2mg of glucose in the 
resuscitation fluid to animals with glucose levels below 75mg/dL.  Although 
plasma glucose level transiently increased, hypoglycemia persisted and survival 
rate was not improved by inclusion of this treatment (data not shown).   
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Figure 3.3   Late intervention with antibiotics and fluid resuscitation 
rescues the majority of mice from otherwise lethal sepsis.  All animals 
were given a lethal dose of cecal slurry (CS).  Mice received antibiotic 
treatment alone (imipenem, IPM; 1.5mg i.p.), fluid resuscitation alone (1mL 
physiological saline, s.c.), or a combination treatment of antibiotics and fluid 
resuscitation (n=5-9 per group) beginning 12 or 24 hours after CS injection.  
Therapeutic treatment was continued twice daily for five days.  (A) Survival 
and (B) body temperature were monitored for multiple days.  Data is 
represented as mean ± standard deviation.  (C) Circulating bacteria load was 
assessed in the combination treatment groups by culturing blood obtained by 
micropuncture of the tail vein immediately before the first therapeutic treatment 
(12h), after 3 treatments (48h) and after 7 treatments (96h). Symbols * and *** 
represent p<0.05 and p<0.001 respectively compared to no intervention group; 
††† represents p<0.001 respectively compared to bacteria load before 
intervention (i.e. 12 and 24h).  Figure adapted from Steele et al. 2017. 
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Figure 3.4.  Mild temperature regulation did not further improve survival 
in mice which received antibiotic and fluid resuscitation.  Middle-aged 
mice (16 months old) were all administered a lethal dose of CS and received 
therapeutic intervention with the antibiotic imipenem (IPM) and fluids 
beginning 12h later.  The cages of one group (n=9 mice) were positioned half-
on heating pads at this time so that the bedding was mildly warm (between 32 
and 33°C), and the remaining mice (n=9) were kept only at room temperature 
(21-23°C).  (A) Rectal body temperature and (B) survival were monitored.    
* notates p < 0.05, *** notates p < 0.001.   
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We hypothesized that treating hypothermia using mild cage warming may 
further improve survival.  Therefore, an experiment was conducted in which all 
animals were given sepsis and were resuscitated beginning at 12h as in Figure 
3.3, and cages were either kept at room temperature, or were placed with half of 
the cage bottom on heating pads so that the bedding was 32-33°C throughout 
the resuscitation time-course.  Such mild cage warming resulted in successful 
improvement in body temperature compared to animals which received only the 
antibiotics and fluid resuscitation (34.1 ± 0.7 vs. 29.4 ± 1.6, p<0.001; Figure 3.4 
A), but did not improve survival (56% vs. 67%; Figure 3.4 B).   
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To determine whether high survival is still achievable if therapeutic 
intervention was postponed even further, combination treatment with antibiotic 
and fluid resuscitation was delayed until 24h after CS injection.  This therapeutic 
timeline resulted in 50% 10-day survival rate (Figure 3.5 A).  The survivors of 
this delayed intervention exhibited prolonged hypothermia for 48h post-CS 
injection (Figure 3.5 B).  Surviving animals recovered body temperature 
(36.5±0.8°C) 96h after CS injection (72h after therapeutic intervention).  
Bacteremia was confirmed at 24h after CS injection and bacteria load was 
reduced after 3 treatments with therapeutics (72h after CS injection) and was 
resolved after  7 treatments (108h after CS injection, Figure 3.5 C), similar to the 
trend observed in the animals that were resuscitated beginning at 12h post-CS 
injection. 
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Figure 3.5 Further delay in therapeutic intervention with antibiotics and 
fluid resuscitation to 24 hours post-CS injection results in 50% survival.  
All animals were given a lethal dose of cecal slurry (CS).  Mice either received 
no further treatment (n=5), or were administered the therapeutic resuscitation 
protocol (antibiotic treatment and fluid resuscitation twice daily; n=6), 
beginning 24h after CS injection and continued twice daily through day 5.  (A) 
Survival and (B) body temperature were monitored for multiple days.  Data is 
represented as mean ± standard deviation.  (C) Circulating bacteria load was 
assessed in the resuscitated animals immediately before therapeutic 
intervention, after 3 treatments, and after 7 treatments. * and *** represent 
p<0.05 and p<0.001 respectively compared to no intervention group; † 
represents p<0.05 compared to bacteria load before intervention.  Figure 
adapted from Steele et al. 2017. 
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3.4.3 Delayed, but not early, therapeutic intervention allows for the development 
of cytokinemia, organ dysfunction, and sustained body weight loss 
Next we aimed to determine if delayed therapeutic intervention resulted in 
clinically-relevant characteristics of severe sepsis.  Severe infection was initiated 
by CS injection and animals received either early (≤6 hours) intervention with 
antibiotics or late (≥12 hours) intervention with combination treatment of 
antibiotics and fluid resuscitation.  Plasma samples were prepared at the time of 
euthanasia (24 hours after CS injection) and interleukin-6 (IL-6), interleukin 1β 
(IL-1β), and tumor necrosis factor α (TNFα) levels were assayed.  As shown in 
Figure 3.6, non-resuscitated animals had significantly higher levels of all three 
proinflammatory cytokines 24 hours after CS injection (the time at which half of 
animals could still be rescued using repeated antibiotic and fluid treatment) 
compared to non-sepsis controls (p<0.05).  Although significance was not 
achieved, on average the 12h resuscitated group had elevated cytokine levels 
compared to non-sepsis controls (18,028 pg/mL vs. nondetectable IL-6 levels, 
46.1 vs 18.4 pg/mL IL-1β levels, and 67.1 vs. 5.0 pg/mL TNFα levels).  Similarly, 
the 12h resuscitated group had higher cytokine levels on average compared to 
that of the early (≤6 hours) resuscitated groups.  A similar trend was observed 
without statistical significance when the anti-inflammatory cytokine interleukin 10 
(IL-10) levels were compared among the groups.   
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Figure 3.6 Early, but not late, therapeutic intervention blunts CS-induced 
cytokinemia.  Severe infection was induced by cecal slurry (CS) injection and 
mice were divided into groups (n=4-8).  Mice received antibiotic treatment 
(imipenem, 1.5 mg/mouse, i.p.) beginning 1 or 6 hours after CS injection, or 
combination treatment with antibiotics and fluid resuscitation (physiological 
saline, s.c.) beginning 12 hours later.  A group of animals (n=4) received 
vehicle injection (10% glycerol-PBS) for comparison (non-sepsis).  Plasma 
samples obtained 24 hours after CS injection were subjected to (A) IL-6, (B) 
IL-1β, (C) TNFα, and (D) IL-10 quantification.  * indicates p<0.05 by one-way 
ANOVA.  Figure adapted from Steele et al. 2017. 
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Figure 3.7 Late, but not early, therapeutic intervention results in 
prolonged reduction in body weight.  Severe infection was induced by cecal 
slurry (CS) injection and mice were divided into groups (n=4-8).  Mice received 
antibiotic treatment (imipenem, 1.5 mg/mouse, i.p.) beginning 1 or 6 hours 
after CS injection, or combination treatment with antibiotics and fluid 
resuscitation (physiological saline, s.c.) beginning 12 hours later.  (A) Body 
weight was monitored for 14 days after CS injection (n=5-9).  (B) In a separate 
experiment, the body weight of animals resuscitated with antibiotics and fluid 
resuscitation beginning 12 hours after CS injection was monitored up to 30 
days post-CS injection (n=7).  †† indicates p<0.01 at all time-points compared 
to baseline (paired student’s t-test).  Figure adapted from Steele et al. 2017. 
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In order to assess potential long-term effects of delaying therapeutic 
intervention, the body weight of each mouse was monitored for 14 days after CS 
injection.  Mice which received early intervention (starting at 1h or 6h) 
experienced rapid recovery of body weight (> 95% or >90% of original body 
weight by 7 days, respectively), whereas delayed intervention (starting at 12h or 
24h) resulted in long term body weight depression (<85% original body weight by 
day 7, and <90% by day 14, p<0.05 early time-points vs late time-points; Figure 
3.7 A).  In another experiment under the same sepsis and therapeutic conditions, 
we confirmed that the sepsis-induced reduction in body weight (<90% original) 
persisted for at least 4 weeks (Figure 3.7 B).   
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Figure 3.8 Abscesses were detected in surviving mice two weeks after 
sepsis induction by cecal slurry with late therapeutic intervention. A 
small abscess on the liver surface (A) and a larger abscess on the visceral 
adipose tissue (B) are shown as examples. Figure adapted from 
supplementary data shown in Steele et al. 2017. 
 
BA
Delayed therapeutic intervention also resulted in abscess formation which 
was identified in approximately half of the animals two weeks after sepsis 
induction (Figure 3.8). 
 
 
To evaluate the effect of timing of therapeutic intervention on sepsis-
induced organ injury, lung injury of animals euthanized 24 hours after CS 
injection was histologically examined.  As shown in Figure 3.9, H&E staining of 
tissue sections revealed that late resuscitation, started ≥12 hours after CS 
injection, resulted in pathological abnormalities including infiltration of 
inflammatory cells, marked edema in the interstitial space, and thickened alveolar 
walls.  The average composite lung injury score of 12-hour intervention group 
(7.5) was equivalent to the non-intervention group’s average score (7.8), both 
being much higher than the control group (0.8). Conversely, animals which 
received early intervention (1 or 6 hours after CS injection) showed few markers 
of inflammation (average composite score of 2.2).  The inflammatory scores of 
the 12 hour and non-resuscitated groups were significantly higher compared to 
the early resuscitated groups (1 and 6 hours) (p<0.001).  
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Figure 3.9 Early, but not late, therapeutic intervention prevents sepsis-
induced lung injury.  Mice received cecal slurry (CS; n=14) or vehicle (10% 
glycerol; n=4) injection.  CS-injected mice were divided among groups: non-
resuscitated, 1h antibiotics, 6h antibiotics, or 12h combination treatment with 
antibiotics and fluid resuscitation (n=3-4 / group).  All animals were euthanized 
24h after CS or vehicle injection.  (A-E) Representative images of lung tissue 
sections stained with H&E (400X, scale bar represents 50 µm) are shown.  (F)  
Hisopathological scoring (n=3-4 per group). * represents p<0.05.  Figure 
adapted from Steele et al. 2017. 
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Figure 3.10  Delayed therapeutic intervention results in heightened 
plasma ALT levels.  Animals were divided among treatment groups as 
described in Figure 3.9.  Plasma samples obtained 24 hours after CS injection 
were subjected to ALT quantification by colorimetric assay (n=3-4 per group).  
* indicates p<0.05.  Figure adapted from Steele et al. 2017. 
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To further assess the effect of delaying therapeutic intervention on organ 
injury, plasma alanine aminotransferase (ALT), a commonly used marker of liver 
damage, was quantified in the samples obtained 24 hours after CS or vehicle 
injection.  As displayed in Figure 3.10, the ALT levels of animals which received 
delayed intervention (12 hours after CS injection) was comparable to those which 
did not receive therapeutics (63.2 and 69.9 ng/µL, respectively) (p<0.05) which 
were both statistically higher than the vehicle injected non-sepsis controls (14.2 
ng/µL).  ALT levels in animals which received early therapeutic intervention (1 
and 6 hours after CS injection) showed moderate but non-significant ALT 
increases compared to controls.   Together, these data suggest that delaying 
intervention to late time-points allows pathological characteristics of severe 
sepsis to develop, which were not observed in early intervention groups. 
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3.5 Discussion 
To mimic the clinical situation, antibiotics are often included in animal 
models of sepsis. However, most of the studies using these animal models 
intervene either immediately or within a few hours after infectious insult.  Since 
previous studies have not evaluated the effect of the timing of therapeutic 
intervention in relation to timing of bacteremia after induction of severe infection 
in animal models, there has been a question on whether therapeutic intervention 
is conducted in a manner to maximize survival without allowing severe sepsis to 
develop.  We hypothesized that intervention, if initiated before the development 
of bacteremia, would halt the progression from local to systemic infection and 
block downstream pathology otherwise characteristic of severe sepsis.  On the 
other hand, we hypothesized that delaying intervention until after bacteria is 
detectable in circulation would allow propagation of the inflammatory cascade 
and organ damage, but still result in a high survival rate if the therapeutic 
strategy is aggressive.   
For this study, the cecal slurry (CS) injection model was ideal due to being 
highly time efficient, allowing the induction of sepsis in a large number of animals 
within a short period of time (Gentile et al 2014; Shrum et al 2014; Sam et al 
1997).  Additionally, it is highly reproducible using our new CS preparation 
protocol (Starr, Steele et al 2014; Starr, Steele et al 2017).  Using this model, we 
showed that bacteria are not always detectable in the circulation of animals until 
12 hours after injection with a lethal dose of CS.  Only 25% of animals were 
positive for circulating bacteria 1 hour after CS injection, and even 6 hours after 
CS injection, 50% of animals remained negative for circulating bacteria.  
Using these data, we attempted to establish an intervention model which 
is initiated after all animals are positive for bacteria in the circulation (i.e. ≥12h 
after sepsis induction).  Initiating antibiotic therapy prior to this time-point resulted 
in relatively high survival rates: i.e. intervention at 1 and 6 hours resulted in 80 
and 60% survival, respectively, which is in agreement of the study by Gonnert et 
al. (2011) in which antibiotic therapy initiated 2 hours after CS injection resulted 
in a 50% survival rate. However, our data indicate that many of these animals did 
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not develop sepsis at such early time points.  When we delayed intervention until 
late time-points (≥12 hours when bacteremia is apparent in all mice), antibiotic 
treatment alone could not rescue the majority of animals and >67% died within 4 
days.  Importantly, the blood bacteria of moribund animals (determined by body 
temperature less than 32°C for over 24 hours following CS injection) were unable 
to grow in the presence of IPM when cultured on agar plates containing the 
antibiotic.  This evidence verifies that mortality in this model is not a result of 
antibiotic resistance of the circulating bacteria. 
 We then attempted to increase survival rates of animals under late 
intervention by including fluid resuscitation to reduce hypotension, another lethal 
component of sepsis.  In attempt to mimic the continuous fluid resuscitation state 
without the use of anesthesia, we conducted fluid resuscitation via subcutaneous 
injection two times a day.  We observed a significant improvement in survival rate 
(≥75% of animals with otherwise completely lethal sepsis) when antibiotic 
treatment and fluid resuscitation were given in combination starting 12 hours 
after sepsis induction. This 75% survival rate by the combined treatment is a 
striking improvement compared to 29% by antibiotics alone and 13% by fluid 
resuscitation alone.  Our recent study confirmed that this resuscitation protocol 
can effectively rescue approximately 70% of older mice as well (data not shown).  
Importantly, when the combined therapeutic intervention was further delayed for 
a full 24 hours after CS injection, half of the animals could still be rescued using 
this combination treatment.  In these experiments, some of the animals with the 
most severe bacteremia could be rescued using the combination treatment.  This 
demonstrates the effectiveness of this resuscitation protocol, especially since our 
group previously showed that without therapeutic intervention, bacteremia 
following CS injection correlated with 15 day survival (Starr, Steele et al 2014). 
 In this study, we also provided data demonstrating that animals with late 
intervention, but not early intervention, develop pathophysiological conditions that 
are characteristics of sepsis. We found that intervening after bacteria was 
confirmed in circulation (≥12 hours after CS injection) resulted in the elevation of 
plasma IL-6, IL-1β, and TNFα levels 24 hours after CS injection when compared 
56 
to animals in which therapeutic intervention was initiated at early (1 and 6 hours) 
time-points.  Further, late intervention resulted in marked lung injury, 
characterized by inflammatory cells, thickened alveolar walls, and edema, as well 
as liver damage assessed by heightened plasma ALT levels.  We also found that 
surviving animals of the late intervention groups exhibited an inability to recover 
body weight for four weeks after sepsis.  Being that the majority of animals 
showed no signs of body weight recovery beyond the 1 week time-point, it is 
highly likely that these mice will have reduced body weight beyond this 4-week 
time-point.  Therefore, we conclude that our experimental sepsis model with late 
intervention allows for good survival rates with development of severe sepsis, 
organ injury, and long-term body weight reduction, as opposed to sepsis models 
with early intervention which tend to blunt pathophysiological processes, and 
sepsis models without intervention which result in high early mortality.  
We predict that this late therapeutic strategy would be highly applicable to 
other animal models of sepsis, including the widely used CLP model.  The CS 
and CLP models are similar in that they induce severe intra-abdominal infections 
via exposure to endogenously-derived polymicrobial bacteria.  Indeed, many 
have found that antibiotic administration after CLP significantly improves survival 
(Newcomb et al 1998; Coopersmith et al 2003; Brown et al 2015; Baker et al 
1983), especially in the young (Turnbull et al 2003).    When administration of 
antibiotics was delayed until 12 hours after CLP and given every 12 hours for 5 
days, animals with IL-6 levels >14,000 pg/mL at 6 hours were unable to be 
rescued (Turnbull et al 2004).  In our model, the average IL-6 level were higher 
than the cutoff set by Turnbull et al, (106,445 pg/mL at 24 hours after CS 
injection).  We too found that animals were not able to be rescued using 
antibiotics alone, however, survival was achieved in half of the animals when 
given combination treatment, despite having 7-times greater IL-6 levels than the 
cutoff established by Turnbull et al.  Thus, we have reason to believe that if this 
resuscitation strategy were applied to the CLP model, similar survival rate would 
be achieved.  Important to note, the development of bacteremia in the CLP 
model is presumably slower than what we observed in the CS model because 
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the cecal contents may leak more slowly into the peritoneum in the CLP model 
as opposed to the bolus injection of cecal contents in the CS model.  Therefore, 
the more clinically relevant appropriate time of intervention may need to be 
determined and therapeutic treatments may need to be continued for more than 
5 days.   
To apply this late-intervention model to other sepsis models or even 
different experimental conditions (i.e. different age, strains, or gender), we 
recommend that the kinetics of bacteremia following infectious insult should first 
be assessed before deciding the time point for therapeutic intervention.  For 
example, bacteremia was confirmed in all mice just 2 hours following CS injection 
to 5-7 day-old neonate mice (Wynn et al 2007), indicating that intervention at 12 
hours may be too late and thus not effective in this case. It is our opinion that this 
protocol, combination treatment with antibiotics and fluid resuscitation performed 
twice daily for multiple days, should be initiated only after bacteremia is 
confirmed to ensure the development of sepsis and a longer disease course. 
 Although this late-intervention protocol is multifactorial, we acknowledge 
that this is not a comprehensive therapeutic strategy.  The infection and 
hypotension aspects of sepsis are targeted therapeutically in this protocol, as 
they are primary concerns clinically.  Although we did not characterize which 
bacteria grew in the blood cultures or the peritoneum, we confirmed that the 
bacteria in both the CS stocks and blood bacteria were not resistant to IPM.  We 
also examined the efficacy of glycemic control in our late-intervention model with 
antibiotic treatment and fluid resuscitation; however it showed no further benefit 
to survival outcome.  In this study we did not include ventilatory support, but 
predict that it would be beneficial not only for clinical relevance but also for 
survival.  However, we aimed to develop a therapeutic strategy which could be 
adopted by many laboratory groups, and prolonged murine ventilation is a 
technically challenging technique which requires specialized equipment and also 
adds variables (such as prolonged use of anesthesia (Muller-Redetzky et al 
2014; Schellekens et al 2015)) to the experiment which is often undesirable, but 
would be worthwhile to include in future experiments.   
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Figure 3.11 Early vs. Late therapeutic intervention: A comparison of 
sepsis outcomes after severe infection in murine models.  Late 
therapeutic intervention starting 12 hours after severe infection allows 
development of severe sepsis with organ injury and long-term weight 
reduction.  Figure adapted from Steele et al. 2017. 
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3.6 Conclusions 
 To the best of our knowledge, this is the first study which examined the 
effect of therapeutic intervention in relation to the kinetics of the development of 
bacteremia following infectious insult in an animal model of sepsis.  Here we 
elucidate a late-intervention combination treatment protocol in which antibiotic 
therapy and fluid resuscitation are repeatedly administered and result in 
significantly improved survival, even after progression from local to systemic 
infection is achieved, as is profound cytokinemia and organ damage 
(characteristics of clinical sepsis).  As summarized in Figure 3.11, late 
intervention with combination therapeutics after infectious insult has several 
advantages over existing sepsis models in which intervention is either not 
performed or initiated at early time points. We recommend use of this new 
procedure as it will allow for more clinically relevant studies on severe sepsis and 
on investigating post intensive care illness. 
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Portions of this chapter were adapted and reprinted by permission from 
Wolters Kluwer:  Steele AM, Starr ME, Saito H (2017). Late Therapeutic 
Intervention with Antibiotics and Fluid Resuscitation allows for a Prolonged 
Disease Course with High Survival in a Severe Murine Model of Sepsis.  Shock 
2017; 47(6):726-734. 
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CHAPTER 4 
Characterization of Muscle Weakness in Sepsis Surviving Mice: 
Muscle Quantity vs. Quality 
4.1 Abstract 
Sepsis is a serious problem among the aging population as both susceptibility 
and mortality increase dramatically with age.  Among survivors, >70% report 
muscle weakness that significantly impacts activities of daily living for years after 
hospital discharge.  The objective of this study was to adapt our 
sepsis/resuscitation protocol using late middle-aged animals (16 month-old 
C57BL/6 male mice) and to then assess muscle strength in the sepsis survivors 
long after bacteremia was resolved.  Further, we sought to assess changes in 
muscle size during and after sepsis to understand the kinetics of sepsis-induced 
atrophy.  To do this, experimental sepsis was induced in 16-month-old male mice 
by cecal slurry (CS) injection.  Antibiotics and fluid resuscitation were 
administered beginning 12-hours after CS injection and were continued twice 
daily for five days to rescue the majority of animals from otherwise lethal sepsis.  
Changes in body weight and composition were monitored during and after 
sepsis.  Skeletal muscles were weighed and harvested from non-sepsis controls, 
animals with sepsis (day 4), and after sepsis (day 14).  Plasma samples were 
also obtained at these time-points.  During sepsis, mice lost an average of 1.7 
grams lean mass by day four (p<0.01) which recovered by Day 10 (p=0.4). Post-
sepsis animals were significantly weaker compared to controls as evaluated by 
ex vivo specific force analysis of the extensor digitorum longus was (p=0.001).   
Mean cross-sectional area of fiber-types (type I, IIa, IIb, and IIx) in the 
gastrocnemius were reduced during sepsis (day 4) but were similar among non-
sepsis controls and post-sepsis, indicating that atrophy was resolved by day 14.  
Histological examination of the tibialis anterior and soleus muscles by H&E and 
ATPase histochemical stain revealed hallmarks of critical care myopathy.  
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Figure 4.1 Sepsis-induced muscle weakness results in the loss of 
independence.  Upon hospital discharge, sepsis survivors were documented 
as being discharged to a nursing care facility, home with hospice, or home 
with no care.  These data were further categorized by patients who previously 
had no limitations of activities of daily living before hospitalization for sepsis 
(A) and those who did have limitations previously to hospitalization (B).  
Adapted from Battle et al. 2014 used under international license CC BY 4.0. 
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Altogether these data suggest that myopathy, rather than atrophy, is the 
underlying primary mechanism of muscle weakness in the post-sepsis condition. 
 
4.2 Introduction 
 As detailed in Section 1.2, sepsis survivors suffer from long-term muscle 
weakness which significantly impacts their quality of life.  Often this results in 
severe limitations in activities of daily living which cause previously independent 
individuals to be discharged to nursing care facilities which is further illustrated in 
Figure 4.1.  (Odden et al 2013; Iwashyna et al 2010).  This lack of a clinically 
relevant model of sepsis has been a critical barrier to identification of the 
mechanisms responsible for sepsis-induced long-term muscle weakness, 
therefore limiting progress in the field.   
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Further, few studies take into account that sepsis is a disease of the aged, 
as introduced in Section 1.4.  Middle-aged individuals are not only at an 
increased risk for developing sepsis than the young, they are also more likely to 
develop post-sepsis dysfunction that persists for years after hospital discharge, 
possibly due to an already sedentary lifestyle, reduced muscle mass, and lower 
protein intake (Contrin et al 2013; Rahman et al 2013).  The middle-aged, who 
comprise 26.4% of the American population, are particularly vulnerable to 
repercussions of sepsis-mediated dysfunction being that they are in their peak 
salary earning years and sepsis-mediated functional limitations threaten their 
ability to return to work (Iwashyna et al 2012; Iwashyna et al 2010; Hofhuis et al 
2008; Battle et al 2014).  Thus, when choosing an animal model of sepsis, age 
should be a careful consideration for clinical translation. 
In the present study we adapted the severe model of murine sepsis with 
delayed but aggressive ICU-like resuscitation (Steele et al. 2017; Chapter 3) and 
demonstrated that middle-aged sepsis-surviving mice exhibit significant muscle 
weakness long after recovering from sepsis pathogenesis (2-weeks after sepsis 
induction).  We found that this long-term muscle weakness is present even after 
sepsis-induced atrophy is resolved, and when strength was normalized to muscle 
size, indicating that post-sepsis chronic muscle weakness in the sepsis survivors 
was due to poor muscle quality, rather than quantity. 
 
4.3 Experimental approach 
Cecal slurry (CS) was prepared as described in Section 7.3 and 
polymicobial abdominal sepsis was induced by bolus CS injection as described in 
Section 7.4 in late middle-aged male mice (16-months-old; C57BL/6) using a 
lethal dose (LD100; 400 µL).  Therapeutic intervention (antibiotics and fluid 
resuscitation) was administered beginning 12 hours after CS injection and 
continued twice daily for at least 5 days, as established using young animals as 
described in Chapter 3 (and in methods section Section 7.6).  Bacterial load 
(Section 7.5) was evaluated immediately before therapeutic intervention, again at 
48 hours (after 3 treatments) and 96 hours (after 7 treatments) after CS injection.   
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Body weight and body composition (fat and lean mass) were assessed 
before, during, and after sepsis using echoMRI technology.  Based on trends of 
lean mass following CS injection observed using echMRI analysis and to better 
understand changes in muscle size after sepsis induction, groups of animals 
were euthanized during sepsis (day 4) and post-sepsis (day 14) along with non-
sepsis controls, and hind-limb skeletal muscles were weighed.  Ex vivo analysis 
of isometric specific force was used to evaluate muscle strength in sepsis 
survivors (day 14) compared to non-sepsis controls and resuscitated-only 
controls (methods described in Section 7.10).  Pilot experiments were also 
conducted to monitor activity as well as strength throughout the sepsis time-
course using grip strength and the inverted hanging test (Figure 7.2).  Skeletal 
muscles from animals during and after sepsis were subjected to histological 
observation by hematoxylin and eosin (H&E) staining.  Adenosine triphosphatase 
(ATPase) histochemistry was also performed using pre-incubation pH 10.2, 
which results in light staining of slow twitch fibers and dark staining of fast twitch 
fibers. 
4.4 Results 
4.4.1 Animals rescued using our sepsis/resuscitation protocol exhibit long-
term muscle weakness 
We first adapted our severe model of sepsis which includes delayed but 
aggressive ICU-like therapy to rescue the majority of mice to middle-aged mice.  
Sepsis was induced by bolus injection of cecal slurry (CS), and animals were 
randomized to two groups: non-resuscitated group (n=10) or therapeutic 
intervention group which received antibiotics (imipenem; IPM) and fluid 
resuscitation initiated at 12-hours after CS injection and continued repeatedly 
twice daily for at least five days (n=54 over the course of several experiments).  
Therapeutic intervention rescued 74.1% of animals from otherwise completely 
lethal (LD100) sepsis (p<0.01, Figure 4.2 A).  Body temperature was significantly 
improved within 12-hours of the first administration of antibiotics and fluids (i.e. 
24-hours post-CS injection), however, on average animals remained hypothermic 
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for several days, demonstrating a prolonged disease time-course similar to 
clinical sepsis (Figure 4.2 B).  This is further supported by bacteremia analysis 
(Figure 4.2 C); all animals developed bacteremia prior to therapeutic 
intervention, however 3X antibiotic administration was not sufficient for bacterial 
clearance in over half (53.3%) of animals, but was resolved by the end of the 
resuscitation time-course (day 4; antibiotics were continued for one more day to 
prevent expansion of potentially ongoing local infection).  Therefore, this delayed 
but aggressive ICU-like resuscitation animal model of sepsis allows for a longer 
disease time-course while also achieving a high survival rate.   
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Figure 4.2 Delayed but aggressive therapeutic intervention rescues the 
majority of middle-aged animals from otherwise lethal sepsis.  Sepsis 
was induced by bolus injection of cecal slurry (CS, i.p.).  A group of animals 
received no further treatment (n=10), and others received therapeutic 
intervention beginning 12-hours after CS injection, and continued twice daily 
for 5 days.  Survival (A; total n=54 animals which received CS injection and 
therapeutic intervention) and body temperature (B) were monitored for 14 
days (body temperature data shown through day 4, when temperatures 
returned to baseline values, n=10 non-resuscitated, n=21 resuscitated).  In the 
group which received therapeutic intervention, circulating bacterial load was 
assessed immediately before the first therapeutic intervention (i.e. 12 hours 
after CS injection), and again on days 2, 4, and 14 (C, n=14). 
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 In the next study, animals were euthanized 14-15 days after CS injection 
along with non-sepsis controls, when animals had been normothermic and clear 
of bacterial load for ≥10 days.  Ex vivo muscle function was assessed by force-
frequency relationship analysis, normalized to physiological cross-sectional area 
to measure specific force (Figure 4.3 A).  Sepsis survivors exhibited a 19.3% 
decrease in maximal specific force compared to non-sepsis controls (Figure 4.3 
B; 152.87 ± 2.17 vs. 189.51 ± 1.99 kN/m2).  To evaluate the possible influence of 
antibiotic administration on muscle function, specific force was measured in 
animals which received vehicle injection (10% glycerol) instead of CS and all 
resuscitation procedures; no change in muscle function was observed (p=0.6 vs. 
non-sepsis controls; 194.89 ± 2.19 kN/m2).  These results demonstrate that this 
cecal slurry induced sepsis protocol with delayed but aggressive ICU-like 
resuscitation produces sepsis surviving animals which have significant muscle 
weakness even long after sepsis itself is resolved, and is not attributable to 
antibiotic treatment. 
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Figure 4.3. Animals rescued from lethal sepsis using our resuscitation 
protocol exhibit long-term muscle weakness.  Sepsis was induced by CS 
injection and animals were resuscitated beginning 12-hours for 5 days and 
animals were euthanized on day 14.  (A) Muscle strength was assessed by ex 
vivo isometric force analysis performed on the EDL of non-sepsis (n=9), 
resuscitation-only (n=7), and sepsis surviving mice (n=10), and the maximum 
specific force (200 Hz) was observed (B).  Data expressed as means ± SD. 
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Figure 4.4.  Female BALB/c mice develop long-term muscle weakness 
after sepsis.  Sepsis was induced cecal slurry injection and animals were 
resuscitated beginning 12-hours after CS injection, and continued twice daily 
for 5 days.  Animals were euthanized on day 14 and muscle strength was 
assessed by ex vivo isometric force analysis performed on the extensor 
digitorum longus (EDL) of non-sepsis control (n=3) and sepsis surviving mice.  
Data expressed as means ± SD. 
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  In a small pilot experiment, sepsis was induced in late middle-aged (18-
month-old) BALB/c female mice and resuscitation was performed as described 
beginning 12 hours after CS injection.  Strength was evaluated in the sepsis 
survivors (n=2) and the females showed a similar trend of muscle weakness 
compared to the non-sepsis controls (n=3) (Figure 4.4) similarly to what was 
observed in male C57BL/6 mice (Figure 4.4), suggesting that post-sepsis muscle 
weakness is not sex specific.  A large limitation in this experiment, however, is 
that it was conducted in a different mouse strain as well as different sex, which 
introduced a large variable.  Therefore a similar experiment must be done in 
female C57BL/6 animals to make conclusive remarks on any influence of sex on 
this phenomenon. 
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Figure 4.5.  Sepsis-induced muscle weakness is not observable using 
behavioral assessments of rodent strength.  Strength was measured using 
hindlimb grip strength (A) and inverted hanging test (B).  Baseline 
measurements were recorded for all animals (n=11).  Animals were 
randomized to non-sepsis control (n=4) and sepsis (n=7) groups.  Strength 
was assessed on day 6 (the day after the resuscitation time-course was 
completed), and again on day 14.  Data are expressed as means ± SD. 
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4.4.2 Behavior-based assessments of rodent strength were not robust enough to 
make conclusions on the progression of muscle weakness in sepsis survivors 
 To evaluate how muscle weakness progressed after sepsis, our initial 
experiments included analysis of grip strength, a commonly performed method 
for evaluating strength in rodents, and the inverted hanging test (shown in Figure 
7.2).  We conducted a small pilot experiment using non-sepsis control animals to 
evaluate the reproducibility of forelimb grip strength, hindlimb grip strength, and 
total grip strength, and found that hindlimb strength was the least variable.  
Therefore, only hindlimb grip strength was used in the subsequent experiment 
which showed no difference among animals that just recovered from sepsis (day 
5 after cecal slurry injection) when compared to baseline or non-sepsis controls, 
which was also true on day 14 (Figure 4.5 A).  On the other hand, both groups 
improved performance in the inverted hanging test (Figure 4.5 B), which likely is 
a result of learning with increased exposure to the task.   
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Figure 4.6.  Spontaneous wheel running activity is reduced after sepsis.  
Animals were split to wheel running cages and acclimated for ten days.  
Spontaneous wheel running was then recorded for five days as the “before” 
measurement.  Animals were randomized to either the sepsis group or non-
sepsis control group which received vehicle injection (10% glycerol-PBS) and 
all therapeutic procedures.  Resuscitation was performed for five days, and 
wheel running was recorded for the two days following completion of the 
resuscitation time course (days 6 and 7 following CS injection).  Data are 
expressed as means ± SD. 
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4.4.3 Sepsis induces long-term changes in activity 
  As assessed by spontaneous wheel running activity, sepsis survivors 
(days 6 & 7 after CS injection) are significantly less active compared to baseline 
(Figure 4.6 p<0.05).  Although this assessment of activity was promising, there 
was a concern on the effect of exercise on immune function and overall sepsis 
pathogenesis, making interpretation of results difficult.   
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Figure 4.7.  Sepsis induces long-term reductions in cage activity.  After a 
one-week acclimation period (data not shown), cage activity was monitored 
before sepsis induction for two weeks (weeks -2 and -1).  Sepsis was induced 
by cecal slurry injection and therapeutic resuscitation was repeatedly 
administered for five days (week 0).  Activity was monitored for three weeks 
after recovery from sepsis (weeks 1, 2, and 3).  The daily number of beam 
breaks were averaged for the week, and data are expressed as these means 
± SEM.  Statistics compare experimental week to the average of pre-sepsis 
weeks. 
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In a small pilot experiment, cage activity was monitored using infra-red 
motion detectors.  Five animals were initially used, however only three animals 
survived sepsis and could be used for analysis.  Animals were split to the activity 
cages and acclimated for one week.  Baseline measurements were recorded for 
two weeks and were largely consistent (Figure 4.7).  Activity was reduced during 
the week of sepsis induction with resuscitation (week 0) and remained 
significantly lower compared to baseline for three weeks (p<0.05 week 1 after 
sepsis, p<0.001 weeks 2 and 3 after sepsis), demonstrating that sepsis induces 
long-term reductions in activity. 
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Figure 4.8.  Circadian rhythm is unchanged in sepsis survivors but sleep 
bout length is increased.  Animals were acclimated for one week in cages 
with infra-red motion detectors, and activity was recorded for two weeks (pre-
sepsis).  Sepsis was induced by cecal slurry injection, therapeutic 
resuscitation was performed, resulting in three sepsis survivors.  Percent 
activity during light and dark phase was calculated for the pre-sepsis period 
and the week after sepsis (days 8-13; A).  Sleep behavior was analyzed using 
piezoelectric recording in non-sepsis controls (n=7) and post-sepsis animals 
(days 8-9 after CS injection; n=9; B).  Data are expressed as means ± SEM. 
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 We then evaluated percentage of activity occurring during light and dark 
phases using the cage activity data acquired using infra-red motion detectors.  
We found that sepsis survivors showed similar percent activity during light phase 
(29.0%) compared to before sepsis (32.7%), indicating that the sepsis survivors 
did not have a circadian rhythm shift (Figure 4.8 A).  However, using 
piezoelectric recording of sleep, we found that duration of sleep bouts during the 
dark phase is significantly increased in sepsis survivors compared to controls 
(Figure 4.8 B), demonstrating that sleep behavior may be altered in sepsis 
survivors. 
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4.4.4 Sepsis-induced atrophy is evident using our sepsis/resuscitation model, 
and is recovered by day 14 after sepsis induction 
To further support this direction, we conducted a series of experiments to 
demonstrate recovery of muscle mass in our sepsis surviving mice.  The body 
weight of animals in the sepsis group steadily declined through day 4 (average 
4.2 ± 0.2 g; 11.6 ± 0.4 %).  After recovery from sepsis (by days 4-5) animals no 
longer lost weight, but did not recover to baseline by the end of the experiment 
on day 14-15 (8.0 ± 0.8% below baseline weight, Figure 4.9 A).  To better 
understand this sustained body weight loss, fat and lean mass were assessed at 
baseline and throughout the experimental time-course using EchoMRI 
technology in non-sepsis controls (n=7) and animals given sepsis (n=11). 
Animals lost an average of 2.41 ± .01 g of fat mass by day 4, and remained 
significantly lower than baseline at the end of the experiment (2.09 ± .01 g, 
p<0.001, Figure 4.9 B).  Lean mass, also, decreased by day 4 (1.7 ± 0.1 g 
compared to baseline) but unlike fat mass, did recover to baseline values by day 
14-15 (p=0.4, Figure 4.9 C).  These results indicate that fat mass primarily 
accounts for the sustained body weight reduction in the murine sepsis survivors.   
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Figure 4.9. Lean mass is reduced during sepsis but recovers by day 14 
after cecal slurry (CS) injection.  Animals either received no treatment (non-
sepsis controls) or CS injection with therapeutic intervention beginning at 12-
hours.  Body weight was monitored daily during resuscitation time-course, and 
on days 7, 10, and 14 (A).   Fat (B) and lean (C) mass were regularly 
analyzed using EchoMRI technology (n=7 non-sepsis controls, n=11 sepsis 
with resuscitation).  Data are expressed as means ± SEM.   n.s. not significant 
(statistically). 
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To more closely evaluate changes in skeletal muscle mass itself at time-
points identified by assessing the kinetics of atrophy in our sepsis model shown 
in Fig. 4.8 B, we euthanized groups of non-sepsis animals, animals with sepsis 
(day 4), and animals recovered from sepsis (day 14) and measured the wet 
weight of multiple hind-limb muscles with different metabolic properties from one 
leg, and muscles from the other leg were preserved for histology (described in 
methodology section) for fiber-type specific cross-sectional area analysis.  The 
wet weight of glycolytic (tibialis anterior and extensor digitorum longus), and 
mixed metabolic type (gastrocnemius) muscles (with similar trend in an oxidative 
muscle, the soleus) were significantly lower in animals with sepsis (p<0.01, 
<0.001, and <0.01, respectively) but were comparable to controls in the post-
sepsis group (p=0.1, 0.2, and 0.1, respectively), again suggesting that muscle 
mass is recovered by day 14 after CS injection, approximately 10 days after 
recovery from sepsis (Figure 4.10).   
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Figure 4.10. Skeletal muscle wet weight is reduced during sepsis but 
recovers to control values by day 14 after cecal slurry (CS) injection.  
Animals either received no treatment (non-sepsis controls) or CS injection with 
therapeutic intervention beginning at 12-hours.  Wet tissue weight of various 
hindlimb skeletal muscles were measured from control (n=17), sepsis (day 4, 
n=7), and post-sepsis (day 14, n=12) animals.   Data are expressed as means 
± SEM.  n.s. not significant (statistically). 
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Finally, cross-sections of skeletal muscles were cut, fluorescently labeled 
for fiber-type, and fiber-type specific cross-sectional area was quantified as a 
robust measure of muscle size.  Similarly to wet muscle weight, the cross-
sectional area for fast-twitch fibers (types IIa, b, and x) as well as slow-twitch 
fibers (type I) were significantly smaller in the muscles from animals with sepsis, 
but were comparable to non-sepsis controls in the post-sepsis animals (day 14, 
Figure 4.11). Together, these data indicate that sepsis surviving mice have 
significant muscle weakness but is not attributable to atrophy; thus dysfunction 
within the myofibers must be the predominant contributing factor. 
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Figure 4.11. Cross-sectional area is reduced in fast-twitch myofibers 
during sepsis but is recovered to that of controls by day 14.  Animals 
either received no treatment (non-sepsis controls) or CS injection with 
therapeutic intervention beginning at 12-hours.  The medial head of the 
gastrocnemius was fiber-typed using immunofluorescent labeling of myosin 
heavy chains for non-sepsis (n=5), sepsis (day 4, n=4), and post-sepsis (day 
14, n=5) groups, and cross-sectional area was measured using a semi-
automated program.   Data are expressed as means ± SEM.  n.s. not 
significant (statistically). 
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4.4.5 Skeletal muscle of sepsis survivors exhibit hallmarks of critical care 
myopathy  
Neuromuscular diseases are often characterized by sets of 
histopathological markers, which are sometimes used as a tool for diagnosis.  
These routine stains used clinically can be insightful for research scientists as 
tools to similarly “diagnose” animals in our research studies.  Thus, we performed 
adenosine triphosphatase (ATPase) histochemical stain (pre-incubation pH: 
10.2) on muscle cross-sections of all three groups (non-sepsis controls, animals 
during sepsis, and animals recovered from sepsis), and compared these sections 
with a serial section stained with hematoxylin and eosin (H&E).  The mosaic of 
glycolytic (darkly stained) fibers and oxidative (lightly stained) fibers is 
comparable among all three groups in both the tibialis anterior and soleus 
muscles, indicating that fiber-type grouping (characteristic of polyneuropathy 
and/or neurogenic atrophy) is not evident in the sepsis survivors.  However, the 
sepsis survivors’ muscle is characterized by numerous fibers with pockets of 
ATPase activity (Figure 4.12, notated by arrows), which is not seen in the 
controls or animals with sepsis.  Serial section with H&E demonstrates that the 
hole is not due to loss of tissue in the cross-section.  These fibers which lack 
ATPase activity have been reported in patients with sepsis or other acute 
inflammatory conditions (Wheeler 1982), and is a common feature of critical 
illness myopathy.  These data indicate that our sepsis animal model closely 
mimics the clinical situation, and further that sepsis survivors have dysfunction 
within the myofiber which may be responsible for the muscle weakness 
phenotype.   
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Figure 4.12  Abnormal pathology is evident in skeletal muscles of murine 
sepsis survivors.  The tibialis anterior and soleus muscles were harvested 
from non-sepsis controls (A), cecal-slurry injected animals during the 
resuscitation timecourse (day 4, B), and post-sepsis animals (day 14, C).   
ATPase histochemical staining (pH 10.2) was performed, which results in 
oxidative fibers stained light, in contrast to glycolytic fibers which stain dark.  
Representative images are shown; yellow arrows indicate ATPase cavities, 
and Serial sections were stained with hematoxylin and eosin (H&E).  Scale bar 
represents 50 µm. 
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4.5 Discussion 
Until this report, mechanisms of chronic muscle weakness in sepsis 
survivors could not be investigated due to lack of a translational animal model.  
Animal models of sepsis previously presented a major dilemma: considerably 
severe sepsis has to be induced in order to produce sustained muscle 
dysfunction, but such severity caused high mortality that largely prevented long-
term experiments.  Thus, currently existing animal models were either severe 
models (with insufficient or no resuscitation) causing early death of most animals, 
or were mild sepsis models which achieve high survival but not muscle 
weakness.  Therefore the great majority of published studies on muscle 
weakness were completed within 72 hours of sepsis induction (Table 1.1; 
Holecek et al 2012) during which systemic inflammation and bacteremia were not 
resolved and thus cannot be considered “post-sepsis.”   
Here, we show that animals rescued from otherwise lethal sepsis using 
our newly adapted ICU-like resuscitation protocol (Steele et al 2017) are 20% 
weaker compared to non-sepsis controls 2-weeks after sepsis induction 
(maximum specific force, p<0.001), which to the best of our knowledge is the 
latest time-point investigated for analysis of tissue function.  Evaluation of muscle 
strength in sepsis survivors is unique to our study where previously published 
reports either study muscle strength during sepsis, or conduct biochemical 
analyses on skeletal muscle after recovery from mild sepsis without conducting 
assessments on muscle function and therefore no associations could be made 
between molecular and functional data. 
  Further, we demonstrate that poor muscle quality, rather than loss of 
muscle mass, is responsible for the sepsis survivors’ muscle weakness in the 
post-sepsis condition.  Using body composition analysis, wet skeletal muscle 
tissue weight measurements, and cross-sectional area quantification of 
myofibers, we show that animals indeed have significant atrophy during sepsis, 
but that muscle mass recovers by the 2-week time-point (i.e. the time at which 
we observed muscle weakness).  However to eliminate any possible discrepancy 
in muscle size among groups, force measurements were normalized to 
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physiological cross-sectional area (i.e. muscle size) to yield specific force 
measurements, which showed that indeed skeletal muscles from sepsis survivors 
have weakness even when adjusted for muscle quantity (Figure 4.3).   
Additionally, our data suggests that polyneuropathy is not primarily 
responsible for muscle weakness in these murine sepsis survivors since we did 
not observe a rightward shift of the force-frequency curve in the low stimulation 
frequency range, which is a defining characteristic of polyneuropathy.  Further, 
we did not observe evidence of denervation which typically results in fiber-type 
grouping (which would have been apparent in the ATPase histochemical stain 
and fiber-type labeling).  Thus, we concluded that myopathy (i.e. dysfunction on 
the myofibrillar level) rather than atrophy or polyneuropathy is the major 
underlying cause of post-sepsis muscle weakness, which is consistent with 
clinical reports (Koch et al 2011). 
Our pilot studies using this animal model of sepsis also indicate that 
activity is depressed in sepsis survivors for at least several weeks (Figure 4.7).  
Additional experiments using larger animal numbers and more sensitive and 
reliable methods of monitoring activity need to be conducted.  We found that the 
infra-red motion detectors are highly variable when comparing the detectors to 
one another, thus making this a screening tool, rather than a robust method on 
which to base conclusions.  Piezoelectric recording for sleep behavior and 
activity monitoring should be conducted in future experiments to follow-up on 
these preliminary findings.   
Further, our data indicate that behavior-based assessments of strength, 
although desirable since euthanasia is not required, also lack sensitivity and 
repeatability and thus were discontinued in our studies.  Other means of physical 
assessment, such as rotarod test for balance and coordination or treadmill 
running test for endurance, could potentially be used in future studies. 
 We believe that these findings are most relevant to the clinical situation 
due to careful use of our animal model.  We adapted our newly established late-
intervention ICU-like severe model of sepsis in which therapeutics (antibiotics 
and fluid resuscitation) are only initiated after the development of bacteremia, 
82 
and are continued twice daily for multiple days to treat the infection.  Further, we 
used late middle-aged mice (16 months old), approximately equivalent to a 50 
year old human (Flurkey et al 2007) which is more representative of the clinical 
population of sepsis patients and those who are highly vulnerable to post-sepsis 
dysfunction as well as the repercussions of such disability.  Also importantly, we 
used the cecal slurry (CS) injection model to induce polymicrobial abdominal 
sepsis, as opposed to the surgical cecal ligation and puncture (CLP) model, 
mainly because mice that survive CLP-induced sepsis have a ligated cecum that 
may affect dietary habits and GI function, in addition to unresolved necrosis 
which may introduce variability in long-term physiological processes. 
 
4.6 Conclusions 
 In summary, the present study demonstrates that sepsis triggers 
significant skeletal muscle weakness which persists long after recovery from 
sepsis pathogenesis itself (14 days after sepsis induction).  Further, we show that 
muscle mass is recovered at this time-point, and no hallmarks of polyneuropathy 
were present, indicating that muscle quality, rather than quantity, is responsible 
for muscle weakness in the murine sepsis survivors.  This conclusion was 
supported by abnormal muscle pathology as observed using ATPase 
histochemical stain.  These data suggest that (A) the choice of animal model 
must be carefully made based on one’s scientific question, paying close attention 
to clinical translation, and (B) sepsis-induced skeletal muscle weakness is not 
due to muscle wasting, but rather dysfunction on the myofibrillar level. 
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CHAPTER 5 
Mitochondrial Myopathy and Oxidative Damage are Associated with 
Chronic Muscle Weakness in Sepsis Survivors 
 
5.1 Abstract 
Published studies aimed at elucidating the underlying mechanism for muscle 
weakness in sepsis survivors have been limited to analysis during sepsis due to 
the lack of an appropriate model.  Despite this limitation, these studies have 
consistently observed mitochondrial dysfunction during sepsis. The objective of 
the current study was to determine if mitochondria remain damaged and 
dysfunctional long after recovery from sepsis pathogenesis. Experimental sepsis 
was induced in 16-month-old mice by cecal slurry injection in combination with 
ICU-like interventions (antibiotic and fluid resuscitation). Two weeks later, 
animals were euthanized and skeletal muscles were processed for transmission 
electron microscopy which revealed enlarged mitochondria with gross 
morphological abnormalities in sepsis-surviving mice.  Respiration analysis and 
evaluation of mitochondrial enzyme activities demonstrated that sepsis survivors 
have impaired mitochondrial function.  As damaged mitochondria produce an 
abundance of free radicals, markers of protein oxidative damage (3-nitrotyrosine 
and protein carbonyls) were evaluated and found to be elevated in skeletal 
muscles of sepsis survivors.  These novel findings indicate that long-term muscle 
weakness in sepsis survivors is accompanied by profound mitochondrial 
myopathy, which likely contributes to muscle weakness through reduced 
myofibrillar volume, decreased energy production, free radical production, and 
protein damage.   
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5.2 Introduction 
 The mechanisms of sepsis-induced muscle weakness have been poorly 
understood due to the lack of an appropriate animal model, which we addressed 
through refinement of the cecal slurry (CS) injection model of sepsis (Chapter 2) 
and ICU-like resuscitation protocol which results in high survival from otherwise 
completely lethal sepsis (Chapter 3).   We then showed that sepsis surviving 
animals indeed have severe muscle weakness two weeks after recovery from 
sepsis pathogenesis (Chapter 4).  Although loss of skeletal muscle mass (i.e. 
atrophy) during sepsis is a well-characterized pathophysiology and has been 
intensively studied in both humans and animals (Holecek 2012; Chai et al 2003; 
Jepson et al 1986; Choo et al 1989; Schefold et al 2010), we demonstrated that 
the murine sepsis survivors have muscle weakness even after atrophy is 
resolved (Section 4.4.2).  Further, there are many documented clinical cases 
wherein long-term post-sepsis muscle weakness persists even without atrophy 
(Baldwin & Bersten et al 2014; Supinski & Callahan 2006; Eikermann et al 2006). 
Additionally, nutritional supplementation after sepsis often does not effectively 
cure skeletal muscle weakness (Lynch et al 2007; Lang et al 2007; Ash & Griffen 
1989). These facts suggest that persistent post-sepsis weakness is likely caused 
by issues of muscle quality rather than quantity. 
Many published studies on muscle dysfunction during sepsis in human 
patients and animal models demonstrated that sepsis induces mitochondrial 
dysfunction.  Reductions in mitochondrial number (Zolfaghari et al 2015; 
Fredriksson et al 2006), electron transport chain enzyme activity (Fredriksson et 
al 2008; Callahan & Supinski 2005; Peruchi et al 2011), and glutathione (Cruzat 
et al 2014; Brealey et al 2004) have been reported, however it is unknown if such 
dysfunction remains unresolved after recovery from sepsis pathogenesis. 
In the present study, we used our sepsis/ICU-like resuscitation protocol 
(Steele et al 2017; Chapter 3) in late middle-aged mice (16 months old, 
equivalent to 50 year old humans) as conducted in Chapter 4.  Using this model, 
we show that skeletal muscle mitochondria are significantly enlarged and have 
frequent structural abnormalities.  Further, we demonstrate that mitochondrial 
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function is significantly impaired long after sepsis is resolved, and that ATP 
content is reduced, demonstrating insufficient electron transport chain activity 
and energy production.  Lastly, since damaged mitochondria produce an 
abundance of free radicals, we evaluate markers of oxidative damage and lipid 
peroxidation, demonstrating that skeletal muscle of sepsis survivors is 
characterized by significant oxidative damage.  Together these data show that 
sepsis survivors suffer from mitochondrial myopathy and oxidative damage long 
after sepsis itself is resolved and are likely major contributors to long-term 
muscle weakness.  
 
5.3 Experimental Approach 
 Late middle-aged mice (16 months old, male C57BL/6) were used for this 
study.  Sepsis was induced by administration of a lethal dose of cecal slurry (CS) 
as described (Chapters 4 & 7) and the non-sepsis control animal received vehicle 
injection (10% glycerol-PBS) and resuscitation procedures.  Animals were 
euthanized 14 days after CS or vehicle injection, and skeletal muscles were 
processed and analyzed using transmission electron microscopy (Section 7.13).  
Five electron micrographs were captured for the intermyofibrillar and 
subsarcolemmal mitochondrial populations, and mitochondrial area was 
quantified using ImageJ software.  Mitochondrial DNA integrity was assessed 
using a classic PCR-based assay (Section 7.15) and quantified using 
densitometry analysis. 
 To evaluate mitochondrial function in skeletal muscle of sepsis survivors, 
two experiments were performed.  First, non-sepsis controls and sepsis survivors 
were euthanized 14 days after CS injection and mitochondria were immediately 
isolated from the tibialis anterior (TA) and soleus muscles and subjected to 
respiration analysis using Seahorse (Section 7.14).  Second, electron transport 
chain enzyme activity was assessed in sepsis survivors as well as in animals 
during sepsis, frozen muscle tissue sections processed for Figure 4.12 were 
used for a series of histochemical stains: nicotinamide adenine dinucleotide 
dehydrogenase (NADH; complex I), succinate dehydrogenase (SDH; complex II), 
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and cytochrome C oxidase (COX; complex IV).  The result of these histochemical 
stains were quantified using Aperio ScanScope software.   
 Finally, sepsis-induced long-term oxidative damage was evaluated in 
protein isolated from the TA of non-sepsis controls and sepsis survivors.  Nitro-
oxidative damage was assessed by western blot for 3-nitrortyrosine, and protein 
carbonyls (i.e. lipid peroxidation) were evaluated using a commercial kit, and 
densitometry analysis was conducted (additional details provided in Section 
7.17).   
 
5.4 Results 
5.4.1 Skeletal muscle mitochondria of sepsis survivors are characterized by 
gross structural abnormalities 
We first used transmission electron microscopy (TEM) to observe 
structural and morphological integrity in the tibialis anterior of sepsis survivors 
(14 days after CS injection, ~10 days after bacterial clearacnce) and 
resuscitated-only controls (n=3 per group).  This revealed gross morphological 
abnormalities among both the intermyofibrillar (Figure 5.1 A) and 
subsarcolemmal (Figure 5.1 B) mitochondrial populations in the sepsis survivors, 
including ruptured outer mitochondrial membranes, broken cristae, and vacuolar 
structures.  The intermyofibrillar mitochondria (responsible for energy production 
for muscle contraction) were enlarged in the sepsis survivors, taking up 30.3 ± 
2.7% more skeletal muscle area compared to controls (Figure 5.1 C) whereas 
this phenomenon was not observed in the subsarcolemmal population (Figure 
5.1 D).   
  
 
  
87 
 
Figure 5.1 Sepsis surviving mice have increased mitochondrial volume 
density and disrupted mitochondrial integrity compared to non-sepsis 
controls.  The extensor digitorum longus (EDL; oxidative hindlimb skeletal 
muscle) was harvested from murine sepsis survivors (2 weeks post-CS 
injection) and non-sepsis controls (n=3 per group) and processed for 
transmission electron microsopy.  Representative micrographs of 
intermyofibrillar (A) and subsarcolemmal (B) mitochondria at 5,000X and 
15,000X magnifications are shown (scale bars represent 500 nm).  
Mitochondrial area was quantified using ImageJ software, and was normalized 
to the non-sepsis controls (analysis of 5 images of each; C, D).  Abnormal 
structure are indicated with the following symbols: broken cristae (stars), 
vacuolar structures (black arrows), disrupted outer membranes (white arrows), 
and fission/fusion (white arrowhead).  Data expressed as means ± SEM. 
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Figure 5.2.  Mitochondrial DNA is not damaged in murine sepsis 
survivors’ skeletal muscle.  DNA was isolated from the extensor digitorum 
longus (EDL) of sepsis survivors (day 14 after cecal slurry injection; n=11) and 
non-sepsis controls (n=10) and PCR was conducted to evaluate mitochondrial 
copy number represented by “short MT” as well as mitochondrial DNA 
damage represented by “long MT” (both adjusted to nuclear DNA).  PCR 
products were visualized using ethidium bromide and quantified using 
densitometry analysis.  Representative bands for non-sepsis controls and 
sepsis survivors are shown, and data is expressed as means ± SD.  n.s. not 
significant (statistically). 
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5.4.2 The integrity of mitochondrial DNA is similar among sepsis survivors and 
non-sepsis controls 
  PCR analysis of mitochondrial DNA yielded two important conclusions: (1) 
mitochondrial copy number is not reduced in sepsis survivors compared to non-
sepsis controls as indicated by no difference in short mitochondrial amplification 
among the two groups (p=0.6), and (2) long amplification of the “hot spot” region 
where mitochondrial DNA point mutations most often occur (Gatlier et al 2006) 
was not different among sepsis survivors compared to controls (p=0.5).  These 
results indicate that although sepsis survivors’ skeletal muscle mitochondria are 
damaged (Fig. 5.1), mitochondrial content seems unchanged and mitochondrial 
DNA is not damaged in the post-sepsis condition. 
 
 
89 
5.4.3 Sepsis induces long-term impairment of mitochondrial function 
Since our TEM analysis revealed mitochondrial damage in the skeletal 
muscle of sepsis survivors, and previous studies in patients and animals have 
revealed mitochondrial dysfunction during sepsis pathogenesis, we hypothesized 
that mitochondria fail to recover function even long after septic insult.   We 
assessed mitochondrial bioenergetics using mitochondrial respiration on 
mitochondria isolated from the tibialis anterior of sepsis survivors (n=9) and non-
sepsis controls (n=6) using the Seahorse Biosciences XF24 Flux Analyzer 
(method described further in Section 7.14; Zhang et al 2012).  The sepsis 
survivors’ mitochondria were significantly impaired in respiratory capacity, where 
the ADP phosphorylation rate (State III) was only 72.7 ± 5.1% that of controls 
(p<0.01; Figure 5.3).  Complex I- driven electron transport chain activity 
(maximal oxidative phosphorylation) was also significantly reduced in sepsis 
survivors (73.4 ± 6.5% of the rate of controls, p<0.05), with a similar trend 
observed for Complex II-driven activity (assessed by adding rotenone, a 
Complex I inhibitor).  Additionally, State IV, in which ATP synthase is inhibited by 
addition of oligomycin, suggests increased electron leakage in the mitochondria 
from sepsis survivors.  Together, these respiration results demonstrate that 
skeletal muscle mitochondria derived from sepsis survivors have significantly 
reduced respiratory capacity (~27% lower compared to controls), as well as 
electron leakage that may further exacerbate muscle dysfunction.   
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Figure 5.3.  Mitochondrial respiration is impaired in sepsis-surviving 
mice.  Mitochondria were isolated from the tibialis anterior of non-sepsis 
control (n=6) and post-sepsis (day 14, n=9) mice, and oxygen consumption 
rate (OCR) was measured in triplicate for each sample.  Oxidative 
phosphorylation (state III) and complex I-driven electron transport (State V-CI) 
were significantly reduced in post-sepsis animals compared to controls, and a 
similar trend was observed in complex II-driven activity.  State IV, in which the 
ATP-synthase inhibitor oligomycin is present, indicates there is greater 
electron leakage in the post-sepsis samples.  Data is represented by means ± 
SEM.  n.s. not significant (statistically). 
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 Being that the respiration analysis was conducted using isolated 
mitochondria which selects for healthier mitochondria and therefore may blunt 
our understanding of the real effect of sepsis on mitochondrial health, a series of 
histochemical stains to evaluate mitochondrial enzyme activities were also 
performed on whole tissue sections (tibialis anterior; TA).  This analysis was 
performed in non-sepsis controls and sepsis survivors, as well as animals during 
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sepsis because we hypothesized that mitochondrial function may continue to 
decline after sepsis due to the electron leakage which likely causes further 
damage.  Staining for complex I enzyme (NADH dehydrogenase) activity showed 
weak, medium, and strongly stained fibers in the controls, due to the mixture of 
fiber-types present in the TA (Figure 5.4 A).  Nicotinamide adenine dinucleotide 
dehydrogenase (NADH) activity decreased during sepsis (day 4; 62.0, 27.7, and 
23.3% reduction in weak, medium, and strongly fibers, respectively; Figure 5.4 
B, D), and further decreased in the medium and strongly active fibers in the 
sepsis survivors (Figure 5.4 C, D).  Similar step-wise reductions in enzyme 
activity were observed in complex II (succinate dehydrogenase; SDH) activity 
(Figure 5.4 E-H) and complex IV (cytochrome C oxidase) activity (Figure 5.4 I-
L).  These data suggest that sepsis induces mitochondrial damage and 
dysfunction (decreased respiratory capacity and reduced enzyme activity), and 
that mitochondrial function is reduced even more after sepsis itself is resolved.   
 
92 
 
Figure 5.4 Mitochondrial enzyme activities are progressively reduced 
over time in sepsis survivors.  Tibialis anterior specimens from experiments 
shown in Figure 4.11 were utilized for histochemical staining of mitochondrial 
enzyme activities.  Staining for nicotinamide adenine dinucleotide 
dehydrogenase (NADH; complex I, A-C), succinate dehydrogenase (SDH; 
complex II, E-G), and cytochrome C oxidase (COX; complex IV, I-K) enzyme 
activity were performed. Quantification was conducted using Aperio 
ImageScope software (D, H, L), and values were normalized to the intensity of 
the controls for weak, moderate, and strong activity (exemplified as W, M, and 
S in panel A).  Arrows indicate cavities of mitochondrial enzyme activity and 
point to the same fiber in serial sections.  Data are expressed as means ± 
SEM.  n.s. not significant. (statistically).  Scale bars represent 50 µm. 
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Figure 5.5.  Energy availability is reduced in the skeletal muscle of 
sepsis survivors.  Vehicle or cecal slurry (CS) were injected to 16-month old 
mice, resuscitation procedures were followed for both groups, and animals 
were euthanized 14 days after injection.  Snap-frozen skeletal muscles were 
pulverized, weighed, and deproteinated before conducting the bioluminescent 
assay for the ATP content in the tibialis anterior (A) and soleus (B) skeletal 
muscles, and Student’s t-test was performed. 
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5.4.4 ATP content is reduced in skeletal muscles of sepsis survivors 
 We next evaluated levels of the energy substrate adenosine triphosphate 
(ATP) in skeletal muscle of non-sepsis controls and post-sepsis mice.  The 
preliminary results suggest that ATP tends to be reduced in sepsis survivors 
compared to controls in both the TA (p<0.05; Figure 5.5 A) and soleus (Figure 
5.5 B).  Three of the four post-sepsis samples which fell below the detection limit 
of the assay in the TA set were from the same animals which fell below the 
detection limit for the soleus set.  This data, although preliminary, suggests that 
energy availability is decreased in the skeletal muscle of sepsis survivors which 
may be in part responsible for chronic muscle weakness.  
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5.4.5 Oxidative damage is present in skeletal muscle of sepsis survivors weeks 
after initial insult 
Sepsis pathogenesis stimulates oxidative damage due to accompanying 
hypotension and hypoxia, and dysregulated host inflammatory response to 
infection.  Additionally, mitochondrial damage results in inability for mitochondria 
to buffer calcium and maintain their role in anti-oxidant activity; instead, damaged 
mitochondria release free radicals, which cause oxidative damage.  Also, since 
the aged have reduced capacity to eliminate damaged proteins through 
proteolysis or autophagy pathways, we hypothesized that the sepsis survivors’ 
skeletal muscle would have persistent oxidative damage.  Whole protein was 
extracted from the TA of control and post-sepsis animals, and western blot for 3-
nitrotyrosine (3-NT) demonstrated that sepsis survivors have over 4X-higher 
nitro-oxidative damage than controls (Figure 5.6 A, p<0.001).  Further, oxidative 
damage was assessed by evaluating protein carbonyl (PC) formation using the 
OxyBlot kit, which similarly showed that sepsis survivors have >5X higher levels 
of PC moieties (Figure 5.6 B, p<0.01) in both high and low molecular weight 
proteins.  These results demonstrate that although heterogeneous, sepsis 
survivors have significant oxidative damage compared to controls, which has 
great implication for protein dysfunction.   
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Figure 5.6.  Elevated oxidative damage is evident in skeletal muscle of sepsis 
survivors long after bacterial clearance.  Protein was isolated from snap-frozen 
tibialis anterior muscles harvested from non-sepsis control animals and post-sepsis 
animals (14 days following cecal slurry injection).  Western blot was performed for 3-
nitortyrosine (3-NT; A) indicative of nitro-oxidative damage, and protein carbonyls 
were assessed using OxyBlot Protein Oxidation Detection Kit (B).  Densitometry 
analysis was performed (C, D), and data is expressed as means ± SD.     
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5.5 Discussion 
 This study is the first which evaluated mitochondrial integrity and function 
in sepsis survivors rather than animals or patients during sepsis.  As shown 
previously in Chapter 4, animals have profound muscle weakness long after 
recovery from sepsis pathogenesis.  Further, muscle weakness persists even 
though muscle mass was recovered, demonstrating that chronic muscle 
weakness in sepsis survivors is primarily due to poor muscle quality rather than 
quantity.  Here we show sepsis survivors suffer from mitochondrial myopathy and 
oxidative damage long after recovery from sepsis itself which are likely 
underlying mechanisms of post-sepsis chronic muscle weakness. 
Such mitochondrial myopathy can contribute to muscle weakness in 
multiple ways.  First, we found that intermyofibrillar mitochondria are enlarged 
and occupy 30% more muscle area compared to controls.  This increase in 
mitochondrial volume area, likely an attempt to increase energy production from 
these damaged organelles, results in a decrease of myofibrillar content, which in 
itself contributes to muscle weakness.   
Second, we show that sepsis survivors have decreased mitochondrial 
respiration by seahorse analysis and mitochondrial complex enzyme activities 
shown in whole tissue by histochemical staining.  Further, adenosine 
triphosphate (ATP) content seems to be reduced in skeletal muscle of sepsis 
survivors, suggesting that sepsis survivors have reduced energy availability.  As 
muscle contraction is an ATP-dependent process, decreased electron transport 
chain activity and reduced ATP content results in an energy crisis and reduced 
myofibrillar interaction.   
In addition to these factors, mitochondrial myopathy contributes to muscle 
weakness through oxidative damage.  Mitochondria produce an abundance of 
superoxide anions as a result of oxidative phosphorylation, and mitochondrial 
damage increases production of reactive oxygen species (ROS; Balaban et al 
2005) which can cause further damage nearby proteins, lipids, and DNA 
(including to the mitochondria itself).  We demonstrate that the skeletal muscle of 
sepsis survivors is indeed characterized by strong oxidative damage as indicated 
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by presence of 3-nitrotyrosine and lipid peroxidation (protein carbonyls).  One 
limitation to the current study is that we have not identified the specific proteins 
that are damaged in the sepsis survivors’ skeletal muscle.  However, the lower 
molecular weight proteins (<25 kDa) are likely mitochondrial proteins, whereas 
the higher molecular weight proteins are more likely to be sarcomeric proteins.  
Since oxidatively damaged proteins are commonly dysfunctional, such profound 
oxidative damage likely yields large consequences in both mitochondrial activity 
and sarcomeric interactions, again contributing to muscle weakness in the post-
septic state.  
The observed mitochondrial myopathy at this late time-point (2 weeks 
after sepsis induction) is that which remains after the natural system for 
mitochondrial quality control have done all that is likely possible.  Although these 
processes are multifaceted and robust, they occur quite rapidly.  Quality-control 
proteases eliminate small amounts of damaged proteins (Baker et al 2011), 
whereas mitochondrial fusion occurs when larger amounts of damaged 
molecules are accumulated.  Fusion results in complementation so that defective 
processes for one of the original mitochondria are compensated by the other to 
restore ATP production.  Fission in cultured fibroblasts resulted in complete 
redistribution of a mitochondrial green fluorescent protein (GFP) from one 
mitochondrion to the other within an hour (Youle et al 2012), suggesting that this 
process is extremely rapid.  Debris and damaged molecules are often 
segregated, and fission takes place where the daughter mitochondrion which 
contains debris is hypopolarized and subject to the next level of quality control: 
autophagy (i.e. mitophagy).  Interestingly, the state of starvation, which occurs 
during the acute phase of sepsis due to inactivity of the animals, can inhibit 
autophagy in attempt to increase ATP production (Rossignol et al 2004).  
Therefore, at this late time-point, endogenous pathways to restore mitochondria 
and their bioenergetics capacity have likely ensued, but may remain a potential 
therapeutic target to prevent or treat post-sepsis muscle weakness. 
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5.6 Conclusions 
 Significant mitochondrial damage and dysfunction result in reduced 
contractile machinery due to increased mitochondrial volume area, reduced 
mitochondrial respiration and energy production, as well as marked oxidative 
damage to skeletal muscle proteins, and these all together likely contribute to 
muscle weakness in sepsis survivors.  Further work is necessary to verify that 
these phenomena persist to even later time-points, and to elucidate therapeutic 
strategies to prevent or repair such damage so that sepsis survivors are able to 
return to healthy and productive lifestyles. 
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CHAPTER 6 
Discussion of Major Findings and Future Directions 
 
6.1 Major findings 
 Chronic muscle weakness is a devastating phenomenon that threatens 
the quality of life and independence of the majority of septic shock survivors.  
Previously productive individuals are commonly discharged to nursing care 
facilities due to the development of functional limitations, including walking, 
cooking, bathing, or even going to bed.  What’s more, these individuals continue 
to acquire additional limitations at a higher rate after hospital discharge 
compared to individuals hospitalized for non-sepsis conditions.   
Although clinicians and research scientists alike acknowledge this 
devastating trend, progress in the field has been limited due to the lack of a 
clinically relevant animal model of sepsis.  The first aim of this project was set to 
resolve this critical barrier.  First, we refined the cecal slurry preparation protocol 
to enable long-term storage without reduced bacterial bioactivity (Chapter 2).  
Next, we developed a late-intervention but aggressive ICU-like therapeutic 
resuscitation protocol which rescues the majority of young animals from 
otherwise lethal sepsis, yet still allows for the development of bacteremia, 
cytokinemia, and multi-organ injury (Chapter 3).  We then adapted this 
sepsis/resuscitation protocol to middle-aged animals (16-months old, 
representative of a 50 year old human) as they are more representative of the 
clinical population, and found that sepsis surviving mice were ~20% weaker 
compared to non-sepsis controls two weeks after sepsis induction (Chapter 4).  
This muscle weakness was not attributable to atrophy as muscle size had 
recovered by this time-point indicating that post-sepsis muscle weakness was 
due to poor muscle quality rather than quantity (Chapter 4).  A 30% increase in 
intermyofibrillar mitochondrial area was observed, as were striking structural 
defects and decreases in mitochondrial respiration and complex enzyme 
activities, indicating that sepsis survivors suffer from multifactorial mitochondrial 
myopathy (Chapter 5).  Further, we showed that skeletal muscle of sepsis 
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survivors is characterized by marked oxidative damage as indicated by 3-
nitrotyrosine and protein carbonyl levels, which likely have strong consequences 
on both mitochondrial and sarcomeric function.   
Together these results highlight the importance of careful consideration of 
animal models in the research design for preclinical studies.  More specifically, 
these results indicate that mitochondrial myopathy and accompanying oxidative 
damage are likely a primary underlying cause of chronic muscle weakness in 
sepsis survivors, whereby mitochondrial-specific anti-oxidant therapy may be a 
potential therapeutic strategy in recovery of muscle strength in sepsis survivors. 
 
6.2 Future directions 
6.2.1 Application of our newly refined protocols to specific and broad research 
questions  
 This model opens the door to answering broad research questions.  First, 
it would be of interest to determine if the murine sepsis survivors have cognitive 
dysfunction as is reported in clinical patients (Iwashyna et al 2010).  Along these 
lines, it would be interesting to evaluate changes in social behavior, as 
depression, anxiety, and post-traumatic stress disorder are more prevalent in 
sepsis survivors compared to the general population (Battle et al 2014).  
Additionally, alterations in circadian rhythms and sleep behavior would be 
another clinically relevant application of the model being that patients suffer from 
sleep disturbances which are first initiated during hospital stay during which 
abnormal secretion of melatonin is detectable (Mundigler et al 2002). 
 Second, since sepsis survivors have a high ongoing mortality rate 
following hospital discharge (Cuthbertson et al 2013) and since decreased 
physical function is linked to poor survival outcomes, this model could be used to 
evaluate timing and causes of mortality following acute recovery from sepsis, and 
their associations with physical decline.  A potential downfall to this study is lack 
of a robust behavioral assessment of muscle strength (i.e. a method which does 
not require euthanasia).  Pilot experiments using the treadmill endurance test or 
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rotarod challenge could be conducted as possible methods to evaluate physical 
function in sepsis surviving mice at multiple time-points until expiration. 
 Using this model, it could be possible to identify the causes of death in the 
non-survivors.  To conduct this study, a large number of animals would be 
required since the mortality rate is ~30%.  However, determining whether 
respiratory failure, which is the main cause of death clinically, is the common 
reason would further validate the clinical translation of our model and its 
application to preclinical experiments.   
 
6.2.2 Further characterization of post-sepsis muscle weakness and cecal slurry 
Now that this ICU-like sepsis/resuscitation model is developed, we can 
further characterize the long-term outcomes in sepsis survivors.  In line with the 
current study, we plan to evaluate muscle strength in sepsis survivors at a later 
time-point.  We will conduct a similar experiment to that in Figure 4.3 where 
groups of sepsis survivors and non-sepsis controls are euthanized and ex vivo 
analysis of strength is performed at 4 weeks and 8 weeks following sepsis.  
During these studies, we plan to utilize piezoelectric cage bottoms to assess not 
only activity, but also sleep behavior, throughout and after sepsis pathogenesis.  
One potential downfall is that mice would have to be individually housed, which 
may negatively impact general health as well as sepsis survival.   These studies 
would confirm that sepsis survivors have muscle weakness that is chronic and 
resembles the clinical situation.  These experiments would provide insight on 
changes in activity, sleep behavior, and circadian rhythms both during and after 
sepsis pathogenesis which would further characterize the post-sepsis condition 
using this novel animal model. 
 Next, we plan to confirm that the sepsis-induced muscle weakness 
phenotype observed in these studies using male C57BL/6 mice is not sex and/or 
strain dependent.  We conducted a small pilot study using middle-aged female 
BALB/c mice which showed a similar trend in muscle weakness 2 weeks after 
sepsis (Figure 4.4), however it would be ideal to confirm the phenotype in female 
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mice of the same strain (C57BL/6) and also male mice of a different strain (i.e. 
BALB/c) separately. 
 To better understand the kinetics of muscle breakdown during sepsis and 
determine the phase at which muscle metabolism balance is restored, we will 
evaluate plasma markers of muscle catabolism throughout the sepsis time 
course, as we see atrophy during the acute phase but not the chronic phase 
(Figures 4.9-4.11).  This simple experiment would help bridge the gap between 
the literatures on acute (i.e. during sepsis pathogenesis; ≤ 72 hours after 
infectious insult) and chronic studies (i.e. after bacteremia and systemic 
inflammation are resolved). 
Our current work clearly demonstrates that skeletal muscle of sepsis 
survivors have profound oxidative damage (4-fold higher levels of 3-NT, and 5-
fold higher levels of protein carbonyls; Figure 5.6), but we have two remaining 
research questions concerning oxidative stress in sepsis survivors.  The first 
question concerns the timing of the oxidative damage to the skeletal muscle 
proteins. We hypothesized that oxidative damage to mitochondria first occurs 
during the acute phase of sepsis pathogenesis, and that the damaged 
mitochondria continue to generate ROS which causes further, and potentially 
accumulative, damage during the chronic phase.  We are especially interested in 
answering this question, and plan on testing our hypothesis by using a transgenic 
mouse strain, MnSOD-TG, which overexpresses superoxide dismutase-2 (also 
referred to as SOD-2; manganese-dependent SOD, MnSOD; Yen et al 1996). 
Mitochondria of these mice are highly protected from oxidative stress, including 
that initiated by endotoxemia (Yen et al 1996; Choumar et al 2011).  Our lab 
currently maintains a breeding colony of these mice, which was originally 
provided by Dr. Daret St. Clair, and we have confirmed significant 
overexpression of MnSOD in the skeletal muscle of these mice (Figure 6.1).   
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Figure 6.1.  Skeletal muscle tissue of MnSOD-TG animals has nearly 3-
fold higher expression of MnSOD.  The gastrocnemius muscle was 
harvested and protein was isolated from untreated wild type and MnSOD-TG 
transgenic mice (n=2 per group). Western blot was performed for MnSOD and 
quantified using densitometry analysis.  Data represent means ± SD. 
 
 
 
 
Using these animals, we will determine whether mitochondria are the 
primary cause of sustained oxidative damage which will help identify promising 
therapeutic targets. Determining the time-points with the most severe oxidative 
damage (i.e. acute or chronic) will better establish the ideal time for therapeutic 
intervention.  
 The second major question regarding oxidative damage in the skeletal 
muscle of sepsis survivors that we hope to answer in the future concerns 
identification of the proteins which are damaged.  Lower molecular weight 
proteins with 3-NT or protein carbonyl modifications observed by western blot 
(Figure 6.6) are likely mitochondrial proteins which are typically ≤ 25 kDa.  These 
modifications would result in decreased mitochondrial function and therefore 
decreased energy production.  On the other hand, modifications observed at 
higher molecular weights may be to sarcomeric proteins which could result in 
decreased force generation (Dalle-Donne et al 2003).  Since we have candidate 
mitochondrial proteins, we will first conduct Western blot analyses with 3-NT and 
double stain the gel for mitochondrial complexes using fluorescently conjugated 
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secondary antibodies to determine if the complex proteins have nitrotyrosine 
residues.  This would indicate that the complex(es) are nitro-oxidatively damaged 
and are likely dysfunctional.  To identify other proteins which have oxidative 
damage, we will pull the proteins down by immunoprecipitation using 3-NT 
antibody, run by western, and use mass spectrometry to identify the proteins.  
This will give better understanding to the functional influence of oxidative damage 
to both mitochondria and sarcomeric function. 
 As our muscle function and molecular analysis studies were performed 
only in middle-aged animals, curiosity has developed as to how the results would 
differ in elderly animals or in young animals.  We hypothesize that young animals 
may not develop chronic muscle weakness, whereas the elderly may be on the 
other end of the spectrum with increased severity and possibly the inability to 
recover muscle size, further contributing to development of muscle weakness.  
Therefore, I propose that a similar set of experiments to that conducted in 
Chapter 4 should be conducted in young (16-week-old, equivalent to 25 year old 
human) and elderly (22-24 month old, equivalent to 65 year old human; Flurkey 
et al 2007) mice, whereby a lethal dose of CS is administered, the majority of 
animals are rescued.  Muscle strength would then be assessed by ex vivo 
analysis and muscle size would be evaluated by body composition analysis, wet 
tissue weight, and cross-sectional area quantification.  Results of such studies 
would not only yield better understanding of the effect of age on risk of long-term 
outcomes, but may contribute to more targeted/individualized therapeutic 
strategies. 
 It may be of interest to elucidate key differences in sepsis-induced muscle 
weakness and mitochondrial myopathy with a non-sepsis animal model of 
intensive care unit acquired weakness (ICUAW).  Thus, comparisons could be 
made between our current data set with similar studies in disuse-mediated 
atrophy alone (mediated by hindlimb suspension) or non-sepsis infectious model, 
such as respiratory infection (mediated by inoculation of a drop of bacterial liquid 
culture in the mouse snare) or non-septic burn injury (mediated by scalding burn 
model).  Understanding the extent to which atrophy and myopathy (specifically 
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mitochondrial myopathy) persist in these models of ICUAW would assist in 
elucidation of more targeted therapies for sepsis and non-sepsis mediated 
muscle dysfunction. 
It would also be insightful to further characterize the cecal slurry which we 
make using our refined preparation protocol (Chapter 2).  Although cecal slurry 
has been a common model of polymicrobial sepsis induction, it had been 
inconvenient due to the necessity of making CS fresh.  We demonstrated that CS 
stored in glycerol-PBS at -80C maintains >99% bioactivity 6 months after 
storage, which we have found is true up to one year after storage (data not 
shown).  We are currently planning an experiment to characterize the 
microbiome of the CS.  We plan to conduct genomic studies to characterize the 
microbiota in both freshly made CS as well as frozen and thawed CS.  Further, 
we plan to identify which bacteria circulate in the blood of animals with sepsis 
after CS-induced sepsis. 
 
6.2.3 Further improvements to the model 
 Refinement of the cecal slurry preparation protocol which allows for long-
term storage, increased reproducibility, and increased efficiency (Starr, Steele et 
al 2014), and the development of an ICU-like therapeutic resuscitation protocol 
(Steele et al 2017) now allows for development of organ dysfunction but still 
results in high survival so that long-term studies can be conducted.  This model 
more closely mimics the clinical characteristics of patients, with lung and liver 
injury during the acute phase, as well as muscle weakness and sub-cellular 
damage during the chronic phase.  However, this model can be further improved 
in several ways. 
  First, to control for the starvation period during the first 24-48 hours after 
sepsis induction, control animals could be pair fed.  This would eliminate the 
influence of malnutrition on the development of muscle weakness; however, 
other groups have already shown that doing so does not result in atrophy and 
thus may be unnecessary (Voisin et al 1996).   
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Second, to mimic the period of bed-rest that patients encounter during 
stay in the ICU, hindlimb suspension could be included during the first ≤96 hours 
so that disuse-mediated mechanisms of muscle weakness may be triggered.  
Doing so is difficult, however, while performing resuscitation procedures every 12 
hours as well as monitoring regularly for body weight and body temperature.  An 
alternative may be to restrict movement by confining animals to a cage with 
significantly reduced area for movement.  Although this does not achieve 
unloading of the skeletal muscles, the muscles would be exercised much less, 
making it more representative to a patient’s stay in the hospital. 
Third, corticoid and/or neuromuscular blocks could be included as they are 
commonly used clinically.  This would further complicate interpretation of results, 
however, being that these agents are suspected of contributing to muscle 
weakness.  Therefore, we would suggest including these drugs only for specific 
research questions. 
Fourth, inclusion of mechanical ventilation would further increase clinical 
translation of this animal model.  Including mechanical ventilation would be 
especially important when studying diaphragm weakness during and after sepsis 
with concern for successful weaning from the ventilator.  “Mouse ICU’s” have 
been established at some research institutions, however mechanical ventilation 
in mice remains a rare skill and thus would not likely be performed by the large 
majority of research groups who may otherwise use this sepsis/resuscitation 
model. 
 
6.2.4 Use of transgenic animals to establish causal relationship between 
mitochondrial myopathy and weakness 
 We showed in Chapter 5 that sepsis survivors have mitochondrial 
myopathy and marked oxidative damage two weeks after sepsis induction, which 
we believe is the primary underlying cause of sepsis-induced chronic muscle 
weakness.  A limitation of the current study is that this is associative in nature, 
not correlative or causative.  Thus, to further establish the link between 
mitochondrial myopathy and its accompanying oxidative damage with muscle 
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Figure 6.2.  MnSOD deficient mice have reduced MnSOD expression in 
skeletal muscles.  Similarly to the experiment shown in Figure 6.1 except 
using MnSOD knockdown transgenic mice, the gastrocnemius muscle was 
harvested, protein isolated, and western blot analysis performed to verify 
reduction of MnSOD expression in the skeletal muscle of these mice.  Data 
represent means ± SD. 
 
 
weakness in sepsis survivors, we plan to utilize mice which are deficient in 
MnSOD (SOD-2; Van Remmen et al 1999; Yen et al 1996).  MnSOD (SOD-2) is 
a mitochondria-specific superoxide dismutase which is an important anti-oxidant 
enzyme that protects the organelle from oxidative stress (Van Remmen et al 
1999).  MnSOD(-/-) homozygous mutant mice are neonatally lethal (Li et al 1996); 
however heterozygous mutant MnSOD(+/-) are born normally, have normal 
lifespans and breed well.  We currently have a breeding colony of these 
MnSOD(+/-) mutant mice, which were provided by Dr. Daret St. Clair, and we have 
confirmed that MnSOD(+/-)  mice have significantly reduced MnSOD expression in 
skeletal muscles (Figure 6.2).   
 
 
 
 
 
 
108 
In a pilot experiment we found that young MnSOD(+/-) mice had increased 
3-NT generation in skeletal muscle compared to wild type mice upon induction of 
sepsis (data not shown) confirming increased sepsis-mediated oxidative stress in 
MnSOD(+/-) mice.  We will test our hypothesis that reduced anti-oxidant protection 
of mitochondria causes increased sepsis-mediated mitochondrial oxidative 
damage which results in more profound muscle weakness in MnSOD(+/-) mice 
compared to  that of wild type animals. With such results, we will conclude that 
increased mitochondrial damage via oxidative stress is linked to long-term 
muscle weakness in sepsis survivors. 
  
6.2.5 Elucidation of therapeutics  
 This body of research indicates that use of anti-oxidant therapy may be 
most appropriate for preventing and/or ameliorating chronic muscle weakness 
after sepsis.  We hypothesize that treatment of mice during or after sepsis with a 
mitochondrial-targeting anti-oxidant will prevent or reduce chronic muscle 
weakness. Bendavia (aka Elamipretide, SS-31) is a promising mitochondria-
targeting anti-oxidant currently in clinical trials.  Several mitochondria-targeting 
anti-oxidants have improved oxidative damage-related pathologies including 
cardiovascular and neurodegenerative diseases (Oyewole et al 2015). However, 
whether such anti-oxidants are effective at preventing and/or ameliorating 
chronic muscle weakness in sepsis survivors has not been determined.   
Further, since not all oxidative damage is mediated by mitochondria, we 
hypothesize that additional treatment with a global anti-oxidant may further 
improve the efficacy.  One such FDA-approved and readily available anti-oxidant 
is N-acetyl cysteine (NAC).  First, it would be ideal to conduct proof-of-concept 
experiments by administering the anti-oxidant(s) immediately before and 
throughout sepsis pathogenesis, as well as during the post-sepsis phase to 
determine if muscle strength is maintained (as opposed to decreasing) and 
further validate that oxidative damage is largely prevented.  The second phase of 
experiments would involve treatment with antioxidants during the resuscitation 
time-course to mimic receiving therapeutic intervention aimed at preventing loss 
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Figure 6.3.  Variable states of autophagy are present in skeletal muscle 
of sepsis survivors. Control mice show LC3-I/II ratio greater than 1. Some 
post-sepsis mice show ratio less than 1 (post-sepsis lanes 3-5) indicating 
appropriate activation of autophagy, whereas others do not. 
 
 
of muscle function while in the ICU; the third phase would involve delaying 
treatment until the chronic phase to determine if treatment can recover muscle 
function after weakness had already developed.  One potential problem with 
including anti-oxidant treatment too early is that it may blunt important immune 
signaling and therefore alter severity and/or mortality.   
 Another potential therapeutic strategy involves activation of autophagy, 
which our preliminary data suggests may not be functioning adequately without 
pharmaceutical intervention.  A low dose of rapamycin or resveratrol, which 
activates autophagy and mitophagy, may be used. We have evaluated LC3 
(microtubule-associated proteins 1A/1B light chain 3B) which shows that 
autophagy is not appropriately activated in some survivors (Figure 6.3) 
supporting this alternative strategy. 
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6.3 Overall summary 
By developing this translational animal model of sepsis with delayed but 
aggressive ICU-like therapeutic intervention, we were able to evaluate muscle 
quantity and quality in sepsis survivors which previously was not possible.  Using 
this new model, we were able to determine that murine sepsis survivors indeed 
have significant muscle weakness long after recovery from sepsis itself.  We 
found that muscle weakness in the sepsis survivors is not attributable to loss of 
muscle mass, but instead is associated with mitochondrial myopathy and marked 
oxidative damage, clearly showing that muscle quality, rather than quantity, is 
responsible for long-term sepsis-induced muscle weakness.  Our results indicate 
that anti-oxidant therapy is likely an effective therapeutic strategy to recover 
muscle strength after sepsis and allow patients to resume a high-quality and 
productive life.   
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CHAPTER 7 
Thesis Methodology 
 
7.1 Animals and husbandry 
Male C57BL/6 mice were used for the large majority of these studies.  
Young adult (16-week-old) mice were acquired from The Jackson Laboratory for 
two purposes: (1) donors of cecal contents for cecal slurry preparation, and (2) 
experiments to establish the ICU-like resuscitation protocol after sepsis induction 
(Aim 1).  Late middle-aged (16-month-old) mice were acquired from the National 
Institute on Aging for all other experiments.  Animals were allowed to acclimate 
for at least 7 days prior to experiments to eliminate influence of transportation 
stress.   
 Animals were maintained in the Division of Laboratory Animal Resources 
at the University of Kentucky.  Mice were housed up to 5 per cage in pressurized 
intraventilated (PIV) cages under controlled temperature (21-23°C), humidity (30-
70%), and lighting (14/10 light/dark cycle) with free access to drinking water and 
chow (Teklad Global No. 2918, 18% Protein Rodent Diet, Madison WI).  All 
experimental procedures were approved by the Institutional Animal Care and 
Use Committee at the University of kentucky.  All animal handling techniques in 
these studies were performed as described and approved in our Animal Use 
Protocol #2009-0541 and were in accordance with the National Institutes of 
Health guidelines for ethical treatment. 
 
7.2 Induction of chronic pancreatitis and diabetes in mice 
To induce chronic pancreatitis in mice, recurrent acute pancreatitis was 
induced in young mice (6-months old) by a procedure modified from our previous 
protocol for acute pancreatitis (Okamura et al 2012). Each mouse received 
intraperitoneal (i.p.) injection with either physiological saline (control) or caerulein 
(American Peptide Company, Sunnyvale, CA) at a dose of 50 mg/kg body 
weight, 6-times hourly, 3 days per week (Monday, Wednesday, and Friday) for 9 
weeks. Body weight of each mouse was monitored daily. To induce diabetes, 
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young (5-months old) fasted mice received streptozotocin (Sigma-Aldrich, St. 
Louis, MO) at a dose of 45 mg/kg body weight, i.p. once daily for 5 consecutive 
days. Control mice received no injection. Development of diabetes was 
confirmed by monitoring the non-fasted blood glucose level of each mouse by tail 
vein nick (ACCU-CHEK Nano blood glucose meter, Roche Diagnostics, 
Indianapolis, IN). 
 
7.3 Cecal slurry stock preparation and characterization 
 Donor mice were euthanized by cervical dislocation and the ceca were 
immediately dissected (Figure 7.1 A), the cecal contents were removed (Figure 
7.1 B) and slurry was made by suspending the cecal contents in 10% glycerol-
PBS at a ratio of 1-mL for every 100mg wet cecal content weight.  The slurry was 
passed through a series of sterile mesh strainers (Figure 7.1 C; 860, 380, 190, 
74µm; Bellco Glass Inc., Vineland NJ) to remove debris.  For maximal recovery, 
a sterile pestle was used to press the slurry through each strainer.  Then, under 
continuous stirring using a magnetic stir bar, the slurry was dispensed into 
cryovials (Figure 7.1 D, 1-2mL each) and stored at -80°C in cell freezing 
containers which ensure slow (-1°C/minute) freezing to maintain bacterial 
viability.  These procedures are summarized in a protocol flowchart (Figure 7.1 
E) which we previously reported in Starr, Steele et al 2014 with minor 
modifications in Steele et al 2017. 
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Figure 7.1.  Protocol for preparation of cecal slurry (CS) for 
cryopreservation.  Cecal contents are aseptically collected from donor 
animals, suspended in 10% glycerol, and passed through a series of mesh 
strainers to remove debris.  The slurry is aliquoted while stirring, and cryovials 
are slowly frozen using freezing containers at -80°C to preserve bacterial 
viability.  Figure adapted from Starr et al 2014 and Steele et al 2017. 
 
A B
DC
Whole ceca are dissected from donor mice.  Cecal
contents are collected and weighed.
Slurry is prepared by suspending cecal contents in 10% 
glycerol-PBS (1-mL for every 100mg).
Slurry is strained through a series of screen  mesh (860, 
380, 190, and 74µm).
Slurry is collected in beaker with a stirring bar.  Aliquots 
are dispensed into cryovials.
Cryovials are frozen at -80°C in a freezing container and 
stored.
E
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Cecal slurry was cultured on agar plates (containing 3.7% w/v brain-heart 
infusion broth and 1.5 % w/v agar) immediately upon stock preparation, and after 
storage at various temperatures (4, -20, and -80°C) for different periods of time 
(up to 6 months).  The cecal slurry was diluted 100-times in sterile saline, plated 
on agar plates, and incubated for 24 ± 2 hours at 37 °C in ambient air.  Colonies 
were counted and colony formation unit (CFU) per mL of cecal slurry was 
calculated.   
 In select experiments, bacteria were cultured on agar plates containing 
antibiotics which select for gram positive (azteonam) and gram negative 
(penicillin G) bacteria to further characterize the bacterial population in the cecal 
slurry.  Further, cecal slurry was cultured on agar plates containing the antibiotic 
imipenem (IPM) at a physiological relevant concentration (relative to the 
concentration in the blood when injected to mice) to determine if the bacteria in 
cecal slurry were resistant to the antibiotic which was subsequently used for 
therapeutic intervention.    
 A CS-containing vial was thawed and heat-inactivated by incubating at 
72°C for 10 minutes.  The resulting heat-treated slurry was administered to mice 
(i.p.) to evaluate the severity of endotoxemia.  A portion was also diluted per 
protocol, and cultured to confirm bacterial death.  Such experiment was repeated 
in both young adult and late middle-aged animals.   
 
7.4 Induction of polymicrobial abdominal sepsis by cecal slurry injection 
Frozen cecal slurry (CS) stocks were thawed rapidly by agitating the 
cryovials in a 37°C water bath immediately before injection.  The CS was mixed 
thoroughly and injected to mice intraperitoneally (i.p.) using a 25-gauge needle.  
To titrate the severity of the model, a series of different doses were administered 
to young, middle-aged, and aged mice, and survival was monitored.  For all 
subsequent studies, a lethal dose of CS (determined to be 500µL in young adult 
mice and 400µL in late middle-aged mice) was administered to induce severe 
infection.  In select experiments, vehicle-injected controls were administered 10% 
glycerol-PBS (i.p.).  Survival was monitored daily for at least 10 days.  Health 
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was assessed by body weight measurements and body temperature using a 
rectal temperature probe (P/N 4600-1.2.6 YSI) daily for 5 days and continued up 
to 14 days. Plasma blood glucose levels were also monitored in select 
experiments using the Accu-Check SmartView system.   
  
7.5 Assessment of bacteremia 
The skin over the tail vein was wiped with alcohol, nicked with a sterile 
razor blade, and 10µL of blood was collected, immediately diluted in 90µL of 
sterile saline, and spread onto agar plates.  In selected experiments, half of the 
blood sample was spread onto agar plates containing antibiotics (2 mg/mL IPM), 
and the remaining half of the blood sample was spread on plates without 
antibiotics.  Plates were incubated at 37°C for 24 ± 2 hours, colonies were 
counted, and CFU was calculated. 
 
7.6 Therapeutic intervention 
 A significant portion of this dissertation project focused on the 
establishment of a novel ICU-like resuscitation model which resulted in rescuing 
the majority of animals from otherwise lethal cecal slurry-induced sepsis.  Initial 
experiments included numerous methodologies: antibiotics, fluid resuscitation, 
pain management, temperature control, and attempted glucose control, which we 
initiated after bacteremia developed in all animals.  Ultimately, a standard 
protocol was established and included administration of antibiotics and fluid 
resuscitation initiated 12-hours after CS-injection, and administered twice daily 
for 5 days thereafter.  A summary of animals used for sepsis experiments shown 
in Chapters 3-5 can be found below in Table 7.1. 
 
7.6.1 Antibiotics and fluid resuscitation 
For antibiotic treatment, imipenem was used as it is a broad-spectrum 
antibiotic with potent capabilities for treating infection and is widely used in 
animal models of sepsis (Marques et al 2013; Kaynar et al 2014).  Imipenem 
(IPM; stabilized in cilastatin) was reconstituted in sterile physiological saline for a 
116 
final concentration of 0.005mg/mL.  The dose of IPM equivalent to the maximum 
dose administered to patients in hospitals was determined to be 1.5 mg.  IPM 
was aliquoted and frozen at -20°C for up to 1 week (under these storage 
conditions IPM maintained 95% efficacy).  For each use, an aliquot was thawed 
in a 37°C water bath and 1.5mg IPM (300µL) was administered i.p. to mice 
beginning 1, 6, 12, or 24 hours after CS injection.  The 1 and 6 hour groups 
received another treatment 12 hours post-CS injection, and all groups then 
received treatments every 12 hours for 5 days or until death.   
In some experiments, fluid resuscitation (700µL, physiological saline, s.c.) 
was administered alone or in addition to the 300µL of antibiotics beginning at 12 
or 24 hours after CS injection.  Antibiotics and fluids were administered twice 
daily.  Antibiotic therapy was continued for 5 days, and fluid resuscitation was 
continued until body temperature recovered to at least 35.0°C.   
7.6.2 Cage warming 
In our initial experiments, temperature control was included as a 
therapeutic treatment.  Since rodents with sepsis become hypothermic, we 
placed each cage on heating pads so that half of the cage was warmed mildly (≤ 
32°C) and the other half of the cage remained at room temperature, giving the 
animals choice of environmental temperature.  The cages were placed on the 
heating pads at 12-hours, when the other resuscitation procedures were initiated. 
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7.7 Analysis of cytokinemia 
 Cytokinemia was evaluated in two sets of experiments: (1) to assess the 
influence of timing of therapeutic intervention on development of cytokinemia in 
young adult animals, and (2) to evaluate long-term low-grade inflammation in late 
middle-aged murine sepsis survivors.   For the first experiment, blood samples 
were obtained from the IVC at the time of euthanasia (10% volume of 0.1M 
sodium citrate was used to prevent clotting during blood collection), and small 
blood samples (≤ 15 µL) were obtained during sepsis and in the sepsis-surviving 
animals by micropuncture of the tail vein for the second experiment.  In both 
cases, blood was immediately centrifuged at 2,500 RPM at 4°C and plasma was 
stored at -80 °C until the biochemical assays were performed.   
 The proinflammatory cytokines interleukin-6 (IL-6), TNF-α, and IL-1β were 
evaluated, as well as the anti-inflammatory cytokine IL-10.  IL-6 was quantified by 
ELISA, and the others were analyzed using a custom multiplex assay from Meso 
Scale Discovery, with the help of the University of Kentucky’s Center for Clinical 
and Translational Science (CCTS).  This assay has increased sensitivity, 
allowing for quantitative measurement of even low concentrations, and also 
maximizes information gained from the same small sample.  Samples were run in 
duplicate for the first experiment, which was not possible in the second 
experiment due to small sample size, but <2% variation in the duplicates for the 
standard curve encourages confidence in the assay.   
 
7.8 Evaluation of lung and liver injury 
 In addition to evaluating cytokinemia to investigate the influence of timing 
of therapeutic intervention after CS injection on sepsis severity, lung and liver 
injury were also evaluated.   
 For histological analysis of lung injury, lungs were slowly infused with 10% 
buffered formalin phosphate from the trachea immediately after euthanasia as we 
previously described (Starr et al 2011; Okamura et al 2012).  After fixation in 10% 
buffered formalin phosphate for 24 hours, the tissues were transferred to PBS 
and embedded in paraffin.  Tissue sections (5µm thick) were cut, mounted on 
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glass slides, and stained with hematoxylin and eosin (H&E).  Photomicrographs 
were taken, and histology was scored in a blinded semi-quantitative fashion 
adapted from the established method by Hirano et al. (2015) with slight 
modifications.  Scoring was conducted for the degrees of (A) alveolar thickening, 
(B) cellular infiltration, (C) hemorrhage, (D) presence of debris, and (E) cellular 
hyperplasia with each assigned a score: 0 (normal; absence of markers), 1 (mild; 
sporadic pathological markers), 2 (moderate; frequent pathological markers) or 3 
(most severe; ubiquitous pathological markers) which were totaled for a final 
score from 0 to 15.  
For biochemical analysis of liver damage, plasma alanine 
aminotransferase (ALT) levels were quantified using a commercially available 
assay kit (Alanine Aminotransferase Activity Colorimetric/Fluorometric Assay Kit, 
Biovision).  Samples were assayed in duplicate, and the duplicates were 
averaged to give one value per sample.   
 
7.9 Assessments of muscle mass 
 To evaluate the kinetics of atrophy during sepsis and to monitor muscle 
mass during sepsis recovery, body composition analysis was performed using 
EchoMRI technology (Body Composition Analyzer, EchoMRI LLC, Houston, TX) 
before sepsis induction, and on days 2-5, 7, 10, and 14 after CS-injection.  
Utilization of this technology in this experiment also gave an understanding of 
changes in fat mass during and after sepsis.   
 The use of EchoMRI technology was especially useful in that changes in 
lean mass could be evaluated over time in the same animals; however, this 
technique is limited in that lean mass is measured in total, which skeletal muscle 
is only a part of, thus changes in skeletal muscle mass are not directly quantified.  
Therefore, we used the information gained using this body composition analysis 
to determine the time-point at which atrophy seems to be most severe (day 4).  
Then we performed an experiment in which a group of animals were sacrificed at 
this time-point (day 4) along with non-sepsis controls and 2-week post-sepsis 
animals.  Hindlimb skeletal muscles of oxidative (soleus), glycolytic (tibialis 
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anterior, extensor digitorum longus), and mixed (gastrocnemius) metabolic 
phenotypes were dissected, blotted, and weighed.   
  
7.10 Muscle strength analysis using an ex vivo system 
 To determine if our sepsis-surviving animals have muscle weakness long 
after sepsis was resolved, late middle-aged animals were injected with a lethal 
dose of cecal slurry and resuscitated beginning 12-hours later, and continued 
twice daily for 5 days.  Sepsis surviving mice were euthanized 2-weeks later (14-
15 days after CS injection; ~10 days after bacterial clearance), and muscle 
strength was assessed by force-frequency analysis on whole muscle samples.  
Non-sepsis controls and controls which received vehicle-injection and the 
resuscitation time-course were also included, and this experiment was repeated 
to ensure that the trends were reproducible.   
At euthanasia, the right hind-limb was immediately placed in oxygenated 
Krebs-Ringer solution (details provided in Table 7.2; 95% O2-5% CO2, pH 7.4).  
The muscle bath was continuously oxygenated while the extensor digitorum 
longus (EDL) was dissected and tethers were placed on the proximal and distal 
tendons using braided silk suture (4-0).  The muscle was freed from the leg, and 
mounted by attaching the tether at the distal end to a fixed hook and the proximal 
end to the lever arm of an ASI 300C‐LR Aurora Scientific transducer system 
(Aurora, Ontario, CA, USA).  The muscle was positioned between platinum 
electrodes and suspended in a temperature-controlled (25°C) chamber 
containing the Krebs-Ringers solution which was continually oxygenated, and 
allowed to acclimate for 5 minutes.   
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Table 7.2. Final Concentration of Working Krebs-Ringers Solution 
Chemical Concentration (mM) 
Sodium chloride 118 
Potassium chloride 4.4 
Magnesium sulfate 1.2 
Monosodium phosphate 1.3 
Calcium chloride 2.5 
Sodium bicarbonate 25 
D-Glucose 10 
 
 
Using an Aurora stimulator (model 701C), the muscle was subjected to 
electrical field stimulation, and resulting force output was recorded using ASI 
610A Dynamic Muscle Control software.  By adjusting the EDL position, the 
maximum twitch force (at 1 Hz stimulation) was found, and digital calipers were 
used to measure the length of the EDL at this position which was defined as 
optimum length (Lo).  Keeping the muscle at Lo, the force-frequency relationship 
was elucidated using stimulus frequencies of 1, 15, 30, 50, 80, 150, and 250 (250 
Hz stimulations were most appropriate for maximum force production for the 
middle aged mice used in these studies, whereas 300 Hz stimulations are 
commonly used when using young animals).  When the protocol was complete, 
the muscle was transferred from the apparatus to a muscle bath where the 
suture tethers where carefully removed from the muscle, then it was gently 
blotted dry and weighed.  To calculate specific force, the physiological cross-
sectional area was estimated according to Brooks & Faulkner (1988).   
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Figure 7.2.  A mouse performing the inverted hanging test as an 
assessment of muscle endurance and coordination.  An animal is placed 
on a wire grid before it is inverted over top of 4 inches of bedding.  Trial times 
are measured and recorded, with a maximum of 10 minutes at which time the 
trial is stopped.  Animals which did not reach the maximum time rested for at 
least 10 minutes and were tested again.  The best of 3 timed trials was used 
per animal. 
 
7.11 Behavioral analyses of strength and activity 
 In attempt to monitor changes in strength over time in the same animals, 
grip strength analysis (hindlimb and total) and inverted hanging test (Figure 7.2) 
were conducted before, during, and after sepsis induction by CS. Animals were 
subjected to three trials for each test, with at least a 10 minute rest time between 
hanging test trials, and the best (i.e. highest) trial was used.   
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Three pilot studies were conducted to assess activity in which animals 
were singly housed in (1) cages with running wheels where number of wheel 
revolutions were recorded, (2) cages with an infra-red motion detector on top 
which recorded the number of beam breaks (both wheel running and activity 
monitoring systems were interfaced with ClockLab data acquisition system 
acquired from Coulbourn Instuments), and (3) cages with Piezo equipment 
(Signals Solutions) which monitors respiratory rate.   
 
7.12 Muscle histochemistry 
7.12.1 Tissue processing 
 The tibialis anterior (TA) and soleus muscles were carefully dissected, 
embedded in a thin layer of optimal cutting temperature (i.e. OCT) compound, 
pinned at resting length to cork board, and immersed in liquid nitrogen-cooled 
isopentane.  After the muscle was snap frozen, the cork board was transferred to 
a dry ice where the muscle was removed and quickly transferred to pre-chilled 
cryovials, and stored at -80°C.  Serial tissue sections (8 µm) were cut, mounted, 
air dried, and stored at -20°C for short term or -80°C for long term storage.   
 
7.12.2 Image acquisition  
 With the exception of immunofluorescently labeled sections, all 
histochemical staining results were observed using Nikon Eclipse E200 
microscope and representative images were acquired using Nikon digital Sight 
DS-U3/DSFil digital software integrated with NIS Elements F3.2 Imaging 
Software (20X magnification).   
 
7.12.3 Hematoxylin and Eosin (H&E) staining and quantification 
 For histological analysis of skeletal muscle samples, hemotoxylin and 
eosin (H&E) staining was conducted.  At least 100 fibers were observed and 
counted for the TA and all fibers were counted for the soleus, and fibers with at 
least one centralized nucleus were counted.  The percent of fibers with 
centralized nuclei were calculated for each sample. 
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7.12.4 ATPase histochemical stain  
 For adenosine triphosphatase (ATPase) histochemical staining, frozen 
sections were fixed with pre-chilled acetone for 20 minutes at -20°C, 
subsequently thawed to room temperature, and placed in racks before being 
immersed in freshly-prepared pH 9.4 pre-incubation solution (0.02 Sodium 
Barbital, 0.036 M Calcium Chloride) for 15 minutes.  The sections were rinsed in 
deionized water, and subsequently immersed in the adenosine triphosphate 
(ATP; 1.3 mM) incubation solution (6.7 mM sodium barbital, 6.0 mM calcium 
chloride) for 15 minutes.  After washing in three changes of 1% calcium chloride 
(~3 minutes each), 10 minute incubation in 2% cobalt chloride, and five washes 
of ~5.0 mM sodium barbital, the sections were submerged in 2% ammonium 
sulfide for approximately 30 seconds.  The sections were rinsed five times, 
dehydrated, and cover-slipped.  It is important to note that the results of this 
assay are dependent on the pH of the pre-incubation solution; in these studies, 
the pH was adjusted to 9.4, which results in type 1 fibers stained light and type 2 
fibers dark.  
 
7.12.5 Immunofluorescent fiber-type staining and semi-automated quantification 
of cross-sectional area  
 For cross-sectional area analysis, fiber-types were determined by staining 
fiber-type specific isoforms of myosin heavy chain (MyHC) as previously 
described (Fry et al 2015).  The frozen sections were thawed to room 
temperature and dried, rehydrated in PBS and subsequently incubated overnight 
at 4°C in the primary antibodies which were acquired from Developmental 
Studies Hybridoma Bank: MyHC type I (1:100; BA.D5; IgG2b), type IIa 
(supernatant; SC.71; IgG1), and type IIb (supernatant; BF.F3; IgM), and type IIx 
fibers remained unstained.  Washing procedures were performed the following 
day (three washes in phosphate buffered saline, five minutes each), and sections 
were incubated in a cocktail of secondary antibodies comprised of 1:250 anti-
mouse IgG2b conjugated with Alexa Fluor 647 (#A21242), 1:500 anti-mouse 
IgG1 conjugated with Alexa Fluor 488 (#A21121), and 1:250 anti-mouse IgM 
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conjugated with Alexa Fluor 555 (#A21426) for sixty minutes at room 
temperature.  Sections were washed, post-fixed with methanol for five minutes, 
and mounted with vector shield mounting media (Vector, #H-1000).  Entire 
muscle cross-sections were imaged using the tiles feature within Zeiss Zen 2 
software (blue edition, v2.0, Zeiss, Oberkochen, Germany) interfaced with a 
Zeiss upright microscope (Zeiss, Oberkochen, Germany).  Fibers were assigned 
as type I, IIa, and IIb depending on intensity within the Cy5, FITC, or Texas Red 
channels, respectively, and unstained fibers were identified as type IIx fibers.  
Cross-sectional area was analyzed on these whole cross-sections using an 
interactive semi-automated analysis program in ZEN (described above).   
 
7.12.6 Histochemical staining of electron transport chain complex enzyme 
activities 
 To evaluate mitochondrial function in whole muscle tissue, a series of 
histochemical stains were performed which result in color deposit upon 
conversion of the substrate by the enzyme.  The intensity of the staining depends 
on mitochondrial density as well as enzyme activity, and result in glycolytic fibers 
stained darker than oxidative fibers.   
 
7.12.6.1 NADH dehydrogenase staining 
 To evaluate mitochondrial complex I activity, the standard NADH 
(nicotinamide adenine dinucleotide) protocol was followed in which thawed 
skeletal muscle sections were incubated in 2.4 mM NADH and nitro-blue 
tetrazolium in 0.5 M Tris buffer for 30 minutes at 37°C.  After fixing using 10% 
phosphate buffered formalin, slides were placed in a rack and rinsed three times 
with deionized water, the sections were washed with a series of ascending then 
descending acetone solutions (30, 60, and 90% in deionized water).  After rinsing 
three additional times in water, the sections were cover-slipped using aqueous 
mounting medium.   
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7.12.6.2 SDH staining 
 To evaluate mitochondrial complex II activity, the SDH (succinate 
dehydrogenase) histochemical staining protocol was followed in which sections 
were incubated in 100 mM sodium succinate salt and 1.2 mM NBT in 0.2 M 
phosphate buffer for 1 hour at 37 °C.  The sections were fixed, rinsed, washed 
with acetone solutions, and cover-slipped as performed during the NADH 
staining procedure (detailed above). 
 
7.12.6.3 COX staining 
 To evaluate mitochondrial complex IV activity, the COX (cytochrome c 
oxidase) histochemical staining protocol was performed in which sections were 
incubated with cytochrome C (1.1 mM), 342 mM sucrose, catalase 
(concentration), and DAB in 0.05 M phosphate buffer for 1 hour at 37 °C.  Next, 
the sections were fixed, washed with deionized water, and dehydrated in 
ascending alcohols and two changes of safe clear, five minutes each while 
agitating, and were permanently mounted.   
 
7.12.6.4 Image quantification using Aperio ScanScope software 
 Whole muscle cross-sections stained with NADH, SDH, and COX 
protocols were quantified using positive-pixel algorithms using ImageScope 
software which generates mean intensity values for weak positive, moderately 
positive, and strong positive fibers for each sample.   
  
7.13 Transmission electron microscopy 
 The tibialis anterior were collected and multiple small pieces (1-2mm 
cubes) from each sample were cut and immersed in fixation buffer comprised of 
2.5% glutaraldehyde and 2.0% paraformaldehyde in 0.1 M sodium cacodylate 
buffer (pH 7.4) overnight.  The tissue samples were post-fixed for 1 hour (1% 
osmiumtetroxide, 1.5% Potassiumferrocyanide), washed in triplicate (deionized 
water), stained for 1 hour (1% uranyl acetate), washed in duplicate, and 
dehydrated in ascending concentrations of alcohol (50, 70, 90, and 100% for ten 
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minutes each, with 100% alcohol step repeated twice) and 1 hour in propylene 
oxide.  Samples were infiltrated overnight in a 1:1 mixture of propylene oxide and 
TAAB Epon, and samples were embedded in TAAB 812 (Epon) resin the 
following day and then polymerized at 60 °C for two days.   
Using the Harvard Medical School Electron Microscopy Facility, ultrathin 
sections (approximately 60 nm) were cut (Reichert Ultracut-S microtome), picked 
up on copper grids stained with lead citrate (0.2%), and examined using a 
TecnaiG² Spirit BioTWIN transmission electron microscope.  At least five fields of 
view of subsarcolemmal and intermyofibrillar mitochondria populations were 
captured for each sample using an AMT 2k CCD camera in a blinded manner.   
ImageJ software was used to measure the area of the mitochondria in 
each micrograph.  The total mitochondrial area per micrograph was calculated, 
and the ratio of mitochondrial to non-mitochondrial area was calculated to portray 
mitochondrial volume density in the skeletal muscle of each sample.   
 
7.14 Mitochondrial isolation and respiration analysis 
The right hind-limb was immediately placed in a muscle bath containing 
ice-cold isolation buffer (215 mM mannitol, 75 mM sucrose, 0.1% bovine serum 
albumin or BSA, 20 mM HEPES, 1mM EGTA; pH 7.2).  The tibialis anterior (TA) 
was quickly dissected while the cold buffer was repeatedly pipetted on the 
muscle.  Once freed, the muscle was transferred to a tube on ice containing the 
isolation buffer; all samples were collected in less than 2 hours.  Trypsin was 
added (final concentration 0.25 mg/mL), the muscle was minced before 
homogenizing on ice in 3 rounds of 5 second intervals (total of 15 seconds; 
motor-driven Potter-Elvehjem homogenizer), and a protease inhibitor cocktail 
(Sigma #P8340; 15 µL) was added to the tissue homogenates.  Mitochondrial 
pellets were obtained through two centrifugation steps at 4°C: the tissue 
homogenates were centrifuged for five minutes at 600 g, the resulting 
supernatant was decanted and then centrifuged at 5,000 g for ten minutes. The 
supernatant was discarded, and the pellet was suspended in isolation buffer, 
protein estimation was performed (BCA protein assay kit acquired from Thermo 
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Scientific).  It was previously shown that this method yields pure mitochondria 
being that the resulting fraction does not express transaminase (Patel et al 
2009).   
 Mitochondrial function was assessed in the isolated mitochondrial 
populations through measurement of oxygen consumption rate (OCR) using 
Seahorse Bioscience XF24 extracellular flux analyzer, as previously reported 
(Patel et al 2014; Sauerbeck et al 2011; Zhang et al 2012) with minor 
modifications.  The 24-well dual-analyzer sensor cartridges (Agilent 
Technologies, Santa Clara CA) were placed in a carbon dioxide-free incubator at 
37 °C the day prior to the experiment.  Once the mitochondria were isolated the 
day of the experiment, the Seahorse Flux Pak cartridges were filled in the 
following manner: (A) pyruvate, malate, and ADP (to yield final conentrations of 5 
mM, 2.5 mM, and 1 mM, respectively), (B) oligomycin (1 µg/mL), (C) 
carbonilcyanide p-triflouromethoxyphenylhydrazone (FCCP; 3 µM), and (D) 
rotenone plus succinate (100 nM and 10 mM, respectively).  The Seahorse 
instrument was calibrated as previously described (Patel et al 2014) using 
mitochondrial protein and respiration buffer (125 mM potassium chloride, 2 mM 
magnesium chloride, 2.5 mM potassium phosphate monobasic, 20 mM HEPES, 
and 0.1% BSA, adjusted to pH 7.2).  The experimental plates contained both 
non-sepsis control and post-sepsis samples in triplicate, and were subjected to 
OCR analysis through the series of dispensing solutions containing substrates 
and inhibitors that were added to injector ports A-D.  ADP phosphorylation 
(oxidative phosphorylation) was stimulated by the Nicotinamide adenine 
dinucleotide (NADH)-linked oxidative substrates pyruvate and malate and ADP 
(State III).  State IV is entered after all ADP has been phosphorylated and ATP 
synthase is inhibited with the addition of oligomycin.  The proton gradient is then 
collapsed by the addition of the uncoupler carbonyl cyanide-p-
trifluoromethoxyphenylhydrazone (FCCP) and maximum electron transport 
activity is evaluated (Complex I-driven State V; NADH-driven respiration).  
Complex I is then inhibited with the addition of rotenone and Complex II-driven 
respiration is assessed by the addition of the substrate succinate (Complex II-
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driven State V).  Rates were generated using the AKOS oxygen consumption 
rate calibration algorithm; the average rate was determined for each sample. 
 
7.15 Analysis of mitochondrial DNA integrity using PCR assay 
 To determine if sepsis survivors’ skeletal muscle had ongoing 
mitochondrial DNA damage, a PCR-based assay was conducted (Hunter et al 
2010) with the assistance of Dr. Tadahide Izumi who graciously provided the 
necessary primers.  DNA was isolated from snap-frozen tibialis anterior (TA) and 
extensor digitorum longus (EDL) samples from non-sepsis controls and 2-week 
post-sepsis groups using a spin-column kit from Invitrogen (PureLink Genomic 
DNA Mini Kit).  The DNA concentration was estimated using a nanodrop 
spectrophotometer (ND-1000) which requires ≤ 2 µL of sample.  Three sets of 
PCR reactions were performed: (1) short mitochondrial DNA, (2) long 
mitochondrial DNA which included the “hot spot” region where >80% of oxidative 
damage occurs, and (3) short genomic DNA (PCR conditions given in Table 7.2, 
primer design shown in Figure 7.3).  After electrophoresis using a horizontal 
system (Life Technologies Horizon 11-14) using 1.5% agarose for short products, 
and 1.2% for long mitochondrial DNA, bands were visualized with ethidium 
bromide, and densitometry analysis was performed.  To assess mitochondrial 
density, short mitochondrial DNA was normalized to short genomic DNA.  To 
assess mitochondrial damage, long mitochondrial DNA was normalized to the 
short mitochondrial DNA.   
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Figure 7.3.  Primer design for PCR-based assay of mitochondrial DNA 
damage. 
 
MT damage 
“hot spot”
“Long amp”
“Short amp”
Table 7.3 PCR conditions 
Amplicon Primer sequence (5'  3') Length (bp) 
Nuclear DNA 
Forward:  
TATGGACCCCCATGAGGAACA 200 Reverse:  
AACCGTCGGCTAAAGACGTG 
Short Mitochondrial  
DNA 
Forward:  
CCCAGCTACTACCATCATTCAAGT 117 Reverse:  
GATGGTTTGGGAGATTGGTTGATG 
Long Mitochondrial 
DNA 
Forward:  
AAAACTAGGCCTCGCCCCATTCCAC 
6,918 Reverse: 
GGAGTGATGATGTGAGGCCATGTGCGA 
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7.16 ATP quantification 
 The tibialis anterior and soleus muscles from non-sepsis controls and 2-
week post-sepsis animals were quickly dissected, placed in pre-chilled cryovials, 
and snap-frozen in liquid nitrogen before being stored at -80 °C.  On the day of 
the assay, samples were pulverized in liquid nitrogen in a cryo-cup (BioSpec 
Products), the pulverized tissue was weighed in a pre-chilled cryovial, and lysis 
buffer was added (10 µL per 10 mg tissue) and samples were incubated at room 
temperature for 10 minutes.  The samples were then deproteinated using 
perchloric acid (final concentration 1M PCA), neutralized with potassium 
hydroxide (pH 6.5-8 determined using litmus paper).  The deproteinated samples 
were centrifuged at 2,500 RMP at 4°C, the supernatant was collected and kept 
on ice.  The assay was performed directly after sample preparation was 
complete. 
ATP content was evaluated using a luminescent commercially available kit 
using 50 µL of the supernatant, which was performed in duplicate for the TA, and 
in singlet for the soleus (due to low volume sample).  ATP content was quantified 
using a standard curve.  
 
7.17 Protein isolation and western blot analysis 
 Skeletal muscles were dissected, placed in cryovials, snap frozen in liquid 
nitrogen, and stored at -80°C until tissues were processed.  Protein was 
extracted using the method described by Feng et al. 2012 with slight adaptations.  
Protein isolation buffer was comprised of 2% SDS, 10% glycerol, 2% 2-
mercaptoethanol, in 50 mM Tris base (pH 7.5), and a protease inhibitor cocktail 
was added (P2714, Sigma).  The muscle samples were homozenized using 
mechanical homogenizers in approximately 20 volumes (w/v) of isolation buffer 
(250 µL and 1.5 mL for soleus and tibialis anterior muscles, respectively) at room 
temperature.  The homogenates were then transferred to 1.5 mL boil-proof 
eppendorf tubes, and placed in an 80°C water bath for five minutes.  The 
samples were then centrifuged at 12,000 g for 10 minutes at room temperature, 
the supernatant was transferred to a new tube and vortexed before aliquoting.  
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Due to the high detergent concentration of the isolation buffer, the protein 
concentration of the samples were evaluated using the Bio-Rad RC DC protein 
assay kit and a standard curve using IgG protein standard.     
 For evaluation of 3-nitrotyrosine residues, the control and post-sepsis 
skeletal muscle samples (20 µg loading protein) were resolved by SDS-PAGE 
electrophoresis (Invitrogen Xcell SureLock midi-system), and proteins were 
electrophoretically transferred (using iBlot system from Bio-Rad) to 
polyvinylidene difluoride (pvdf) membranes (pre-incubated in 100% methanol and 
allowed to dry for 5 minutes).  The membranes were blocked for one hour in 5% 
milk at room temperature, and incubated in 1:3,000 3-nitrotyrosine primary 
antibody (Abcam #ab61392) overnight at 4°C.  The following day, the 
membranes were washed, incubated in 1:10,000 anti-mouse antibody (Santa 
Cruz #2005) for one hour at room temperature, and washed again before 
chemiluminescent detection was performed (WesternBright ECL, Advansta 
Corporation).  Densitometry analysis was performed on the resulting bands, and 
were normalized to Coomassie stain.   
 For evaluation of protein carbonyl formation in the samples, analysis was 
conducted using an OxyBlot kit (EMD Millipore, cat # S7150) using the given 
standard protocol with the minor adjustment of increasing the blocking time to a 
three hour incubation time.  Densitometry and normalization procedures were as 
described above for 3-NT. 
 
7.18 Overall statistical analysis  
 Survival curves were analyzed by Kaplan Meier LogRank test.  Data for 
two-group comparisons were analyzed by Student’s t-test.  When multiple 
comparisons were made, the Shapiro-Wilk normality test was run.  If the data 
passed the normality test, one-way ANOVA and Holm-Sidak post-hoc test were 
used to analyze the data.  Alternatively, when the data was not normally 
distributed, the Kruskal-Wallis test and Dunn’s post-hoc test were used.   In 
instances where one group was assessed multiple times (i.e. bacteria load), 
repeated-measures one-way ANOVA was used, and in times when multiple 
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groups were assessed multiple times (i.e. body temperature data), repeated-
measures two-way ANOVA was used and the Holm-Sidak post-hoc test was run.  
All data are expressed as means and standard deviations and p<0.05 was 
considered statistically significant.  Statistical analyses were performed using 
SigmaPlot Statistical Software version 11.0 (Systat Software, San Jose, CA). 
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Appendix 1.  Abbreviations 
3-NT 3-Nitrotyrosine 
ADL Activities of Daily Living 
ADP Adenosine diphosphate  
ALT Alanine aminotransferase 
ATP Adenosine triphosphate  
CFU Colony forming units 
CIM Critical Illness Myopathy 
CIP Critical Illness Polyneuropathy 
CLP Cecal Ligation and Puncture 
COX Cytochrome c oxidase 
CS Cecal slurry 
EDL Extensor digitorum longus 
FCCP Carbonilcyanide p-triflouromethoxyphenylhydrazone 
FHL Flexor halluces longus 
GM Gastrocnemius 
GSH Glutathione 
ICU Intensive care unit 
ICUAW Intensive care unit-acquired weakness 
LD100 100% lethal dose 
IL-10 Interleukin-10 
IL-1β Interleukin-1beta 
IL-6 Interleukin-6 
i.p. introperitoneal 
IPM Imipenem 
LPS Lipopolysaccharide 
MnSOD Manganese superoxide dismutase 
MOF Multi-organ failure 
MRC Medical research council 
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MRSA Methicillin-resistant Staphylococcus aureus  
MT Mitochondria 
mTOR Mammalian target of rapamycin  
NAC N-acetyl cysteine  
NADH Nicotinamide adenine dinucleotide 
PCR Polymerase chain reaction 
PC Protein carbonyl 
RNS Reactive nitrogen species 
ROS Reactive oxygen species 
s.c. Subcutaneous 
SDH Succinate dehydrogenase 
SIRS Systemic inflammatory response syndrome 
SOD Superoxide dismutase 
SOFA Sequential Organ Failure Assessment 
SS-31 Szeto-Schiller-31 
STZ Streptozotocin 
TA Tibialis anterior 
TNF-α Tumor necrosis factor alpha 
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